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A STUDY OF SERUM LEVEL OF FIBROBLAST GROWTH 
FACTOR-19 IN METABOLIC SYNDROME 
ABSTRACT: 
INTRODUCTION: 
                 Metabolic syndrome is a state of dysregulation of normal body metabolism. 
It is a cluster of Insulin resistance, glucose intolerance, Obesity, Hypertension and 
Atherogenic Dyslipidemia, which are potential risk factors for Type 2 Diabetes 
Mellitus, Cardiovascular diseases and Stroke. FGF 19 (Fibroblast Growth Factor 19) 
is a newly identified metabolic regulator, influencing homeostasis of glucose and lipid 
metabolism. 
AIMS AND OBJECTIVES: 
1. To measure serum FGF19 in patients with Metabolic syndrome and to 
compare the serum level of FGF 19 with healthy individuals. 
2. To analyze the correlation between serum FGF 19 and the 
components of Metabolic syndrome. 
MATERIALS AND METHODS: 
                The study was conducted at Thanjavur Medical College, Thanjavur. The 
study included 50 patients with Metabolic syndrome (25 males, 25 females) and 50 
age and sex matched healthy controls (25 males, 25 females). Anthropometric 
measurements and blood pressure were recorded and fasting blood samples were 
collected. Serum levels of FGF 19 were estimated using sandwich ELISA. Fasting and 
post prandial blood sugars and a complete lipid profile were done for all the samples. 
AIP (Atherogenic Index of Plasma) was calculated for all the subjects. 
RESULTS: 
                Student’s t-test analysis shows a significant decrease in the mean serum 
FGF 19 in cases (135.02 ± 20.76 pg/ml), when compared to the mean serum FGF 19 
in controls (266.34 ± 65.5 pg/ml), which is statistically significant. Pearson correlation 
between FGF 19 and other parameters shows a negative correlation between serum 
FGF 19 and BMI, Waist circumference, systolic and diastolic BP, AIP, fasting and 
post prandial blood sugar, serum TC, TGL, VLDL and LDL concentrations and a 
positive correlation with serum HDL concentration, which are also statistically 
significant. 
CONCLUSION: 
                 This study shows that serum levels of FGF 19 are low in patients with 
Metabolic syndrome. The negative relationship obtained between FGF 19 and several 
other known cardiovascular risk factors like TGL and log (TGL / HDL-C) suggests 
that FGF 19 can be used as a novel marker in assessing cardiovascular risk in patients 
with Metabolic syndrome. Hence, earlier intervention can be taken to reduce the 
cardiovascular complications. 
KEY WORDS: 
                Fibroblast Growth Factor 19, Metabolic syndrome, Insulin resistance, 
glucose intolerance, Obesity, Atherogenic Dyslipidemia, Type 2 Diabetes Mellitus, 
glucose and lipid metabolism. 
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INTRODUCTION 
                    The  Metabolic  syndrome  is  a  major  global  threat  nowadays  due  
to  urbanization,  sedentary  life  style  and  increased  incidence  of  obesity.1   
Metabolic  syndrome  is  a  state  of  dysregulation  of  normal   body  metabolism. 
It is  a  cluster  of  Insulin  resistance,  glucose  intolerance,  Obesity,  
Hypertension  and  Atherogenic  Dyslipidemia,  which  are  potential  risk  factors  
for  Type  2  Diabetes  Mellitus,  Cardiovascular  diseases  and  Stroke.2,3,4 
                    Fibroblast  Growth  Factor  19  (FGF-19)  is  a  unique  member  of  
the  Fibroblast  Growth  Factor  family  of  secreted  proteins.5 It  is  a  hormone  
like  protein  that  regulates  Carbohydrate,  Lipid  and  Bile  acid  metabolism.  
FGF -19  is  synthesized  from  the  small intestine  and  secreted  in  to  the  
circulation  when  bile  acids  are  taken  up  into  the  ileum  after  a  meal  and  
then  acts  on  CNS  to  elicit  its  metabolic  effects. 6,7,8  This  hormone-like  
postprandial  protein  has  recently  been  shown  to  stimulate  glycogen  synthesis  
and  inhibit  gluconeogenesis  through  Insulin  independent  pathways.7,6  It  
stimulates  Hepatic  protein  synthesis  and  Glycogen  synthesis.8 
                    FGF-19  has  recently  been  introduced  as  a  novel  regulator  of  
metabolism,   reversing  diabetes  mellitus,  hyper  lipidemia,  hepatic  steatosis  
and adiposity9. 
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                    In  this  study,  the  aim  is  to  estimate  Serum  levels  of  FGF-19 in  
patients  with  Metabolic  Syndrome  and  to  evaluate  the  relationship  between  
FGF-19  and  other cardiovascular  risk  factors,  there  by  predicting  future  
cardiovascular  complications.  
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REVIEW OF LITERATURE 
METABOLIC SYNDROME 
HISTORIC TRENDS: 
                        The concept of Metabolic syndrome (MetS) started in 1920, when a 
Swedish physician, Kylin associated Hypertension, Hyperglycemia and Gout1,10. 
Then, Vague in 1947, demonstrated the association between Visceral Obesity and 
the metabolic abnormalities in Cardiovascular diseases and Type 2 Diabetes 
Mellitus1. Later, in 1965, an abstract, which again described an entity comprising 
of Obesity, Hypertension and Hyperglycemia, has been presented by Avagadro 
and Crepaldi, at the European Association for the study of Diabetes Annual 
Meeting.1 
                      Then came the very famous Banting lecture in 1988, by Reaven, a 
significant move in the field, which described a cluster of risk factors for 
Cardiovascular disease and Diabetes, and he coined the word  
“SYNDROME X” for this entity 1, 11, 12. He introduced the concept of Insulin 
Resistance, which was a major contribution. But, Visceral Obesity was 
surprisingly being missed in his definition and was later included as a major 
abnormality. Kaplan, in 1989, renamed the entity as “THE DEADLY 
QUARTET”, consisting of glucose intolerance, hypertension, upper body obesity 
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and Hypertriglyceridemia.  Again it was renamed as “THE INSULIN 
RESISTANCE SYNDROME” in 199β.1 
                      Many groups then came forward to develop the diagnostic criteria 
for metabolic syndrome. The World Health Organization (WHO) diabetes group 
made the first attempt to give a definition of the syndrome in 1998, which was 
modified by the European Group for the study of Insulin Resistance (EGIR), in 
19991,13. The next definition was proposed by The National Cholesterol Education 
Program Adult Treatment Panel (NCEP ATP), in 2001. Subsequently, in 2003, the 
American Association of Clinical Endocrinologists (AACE) contributed to the 
Syndrome’s definition. Thus, a desire for a single unifying definition arised. To 
accomplish this need, a new definition was proposed by the International Diabetes 
Federation (IDF), in April 2005.1 
EPIDEMIOLOGY: 
                           Due to epidemic of obesity, as a direct consequence, the 
prevalence of Metabolic syndrome is rising at an alarming rate. Currently, almost 
25% of the US population is affected by MetS, and the problem is worse in 
individuals older than 60 years.3 In diabetic patients, the prevalence was almost 
around 86%.14 
                          In Europe, the prevalence, in individuals of age 40-55 years was 
between 7% and 36% for men and between 5% and 22% for women. The 
frequency of the syndrome varies largely between populations, because of the 
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differing frequencies of the components and different methodologies of 
measurement used.14  
                         Decreased physical activities and increased intake of energy dense 
foods and sugars are the most important contributing factor in the drastic increase 
in the prevalence of Obesity and hence the Metabolic Syndrome15. A huge hike in 
the prevalence of obesity (BMI > 30.0) is also documented by the NHANES 
surveys: 
     NHANES I: 14.1% 
     NHANES II: 14.5% 
     NHANES III: 22.5%. 
                           Metabolic syndrome is a growing health problem, even in 
countries with lower gross national product, due to ingestion of cheap vegetable 
oils and increased urbanization rate15.                                      
CURRENT SCENARIO IN INDIA: 
                            In Asian Indians, the prevalence of the metabolic syndrome 
differs according to the area, the extent of urbanization, patterns of life style and 
cultural or socio-economic factors. According to a recent data, in large cities in 
India, the prevalence accounts for about one-third of the urban population16. 
                         The prevalence of the individual risk factors in Indians is: 
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1. Abdominal obesity - 31.4% 
2. Hypertriglyceridemia - 45.6% 
3. Low HDL - 65.5% 
4. Hypertension - 5.4% 
5. Raised fasting plasma glucose - 26.7% 16  
                        The prevalence of metabolic syndrome in rural areas are 
comparatively low. According to a recent survey, the overall prevalence was 
around 5.0% in rural adults16. 
                        The prevalence of metabolic syndrome in paediatric and adolescent 
population is not uncommon. Because, obesity is prevailing in all age groups, it is 
not surprising that children are not immune to it. The prevalence of obesity in 
urban children in Delhi was found to be 16% in 2002, which increased to 29% in 
2007. The overall prevalence of metabolic syndrome in pediatric population of 
developed countries varies from 3.1% to 12.7%. In India, in adolescent age group, 
it is about 4.2%. No gender difference in distribution was found16. The increasing 
prevalence of obesity in pediatric age group is the main initiating factor of MetS in 
children17.  
                       As pediatric metabolic syndrome is a precursor to adult metabolic 
syndrome, there is no surprise that the prevalence of metabolic syndrome will rise 
up in the upcoming years16. 
                      Almost one third of the population in urban south Asia has MetS. 
Prevalence of Metabolic syndrome, according to various criteria is: 
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 ATP III - 40.3% 
 WHO - 30.6% 
  IDF - 34.9%18 
                       There is variation in the occurrence of MetS among different ethnic 
groups. Reassessment should be done in the criteria defining MetS especially in 
Asian Indians. Cut-offs of WC and BMI in the definition can be modified to yield 
higher rates of diagnosis of MetS19. . 
                       Even though the risk of developing Metabolic syndrome has been 
attributed extensively to life style factors, like smoking, physical inactivity, and 
unhealthy eating habits, certain studies have suggested that the predisposition 
begins in utero20. 
                       In 199β, Hales and Barker proposed “the Thrifty Phenotype”, which 
said that the susceptibility of an offspring to acquire adult chronic diseases occurs 
as a consequence of exposures or insults in the prenatal and postnatal periods20. 
                      In offsprings, epigenetic changes may occur in glucose-insulin 
metabolism causing Insulin resistance and defects in secretion of insulin, as a 
consequence of maternal obesity and Insulin resistance20. 
                     The growing evidence for the association between intrauterine 
environment and the Metabolic syndrome, suggests that the mechanisms causing 
epigenetic changes in the offspring in response to prenatal exposures have to be  
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investigated. With a better understanding of the mechanisms, prediction and 
prevention of complications of pregnancy can be improved, thereby improving the 
betterment of the mother and the offsprings20. 
 
CLINICAL IMPORTANCE OF METABOLIC SYNDROME: 
1. It predisposes to multiple associated disorders. 
2. It serves as a target for treatment and prevention of these disorders. 
3. It is extremely common nowadays21.  
DEFINITION AND DIAGNOSIS: 
                        MetS is considered as disturbance in body metabolism. It involves 
insulin resistance and inflammation. It predisposes to Hypertension, diabetes 
mellitus and atherosclerosis. These diseases in turn increase the risk of CVD22. 
                       The Metabolic syndrome is also designated as: 
 The Insulin Resistance Syndrome,  
 The Syndrome X,  
 The Dysmetabolic Syndrome,  
 HONDA [Hypertension, Obesity, Non-Insulin-Dependent Diabetes 
Mellitus, Dyslipidemia, And Atherosclerotic Cardiovascular Disease]  
 The Deadly Quartet23, 24. 
                       The syndrome is a constellation of clinical findings and laboratory 
values, comprising of Insulin Resistance, Hyper Insulinemia, high blood glucose, 
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Obesity with Dyslipidemia [high Triglycerides and low High-Density Lipoprotein 
Cholesterol] And Hypertension23, 21, 25, 26, 27. 
                       Obesity predisposes to some extent of Insulin Resistance almost 
always. Failure of tissues to respond to Insulin may be due to two reasons: 
i. Reduction in affinity or number of Insulin receptors 
ii. Normal binding of Insulin, but abnormal post receptor responses. 
It is a general rule, that with increase in amount of body fat, there is 
increase in the resistance to Insulin, in the tissues which are normally 
Insulin sensitive28.  
                       The syndrome usually occurs in individuals with frank obesity, but 
can occur in non-obese individuals, with increased abdominal fat29.  
                       The factors defining Metabolic syndrome are interconnected and 
include physiological, biochemical, metabolic and clinical factors1. The risk 
factors include atherogenic dyslipidemia, hypertension, glucose intolerance, 
proinflammatory and a prothrombotic state1,11. They predispose to the risk of 
Cardiovascular disease, Type 2 Diabetes Mellitus and all cause mortality1. 
                      Prothrombotic state is due to: 
i. Increase in pro-coagulant factors – fibrinogen, factor VII. 
ii. Increase in antifibrinolytic factors – Plasminogen Activator Inhibitor –1. 
iii. Platelet aberrations. 
iv. Endothelial dysfunction11, 12. 
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                       Proinflammatory state is due to increase in circulating levels of 
cytokines and acute phase reactants like C-reactive protein11. 
                       The state of chronic, systemic and low-grade inflammation, 
associated with MetS, is involved in the pathogenesis of consequent Insulin 
resistance and atherosclerotic lesions30.   
                     The concurrent presence of MetS and insulin resistance is a high risk 
for developing CVD25.  
                     Insulin sensitivity varies widely in normal individuals. The metabolic 
traits associated with insulin resistance include: 
1. Hyper insulinemia 
2. Some degree of glucose intolerance 
3. Abdominal obesity 
4. Dyslipidemia [high triglycerides, low high-density lipoprotein  cholesterol] 
5. Elevated blood pressure 
6. Elevated c-reactive protein 
7. High Plasminogen Activator Inhibitor – 1 levels 
8. A positive family history of type 2 diabetes mellitus31, 29. 
                     In patients with Metabolic syndrome, the risk of mortality from 
Cardiovascular problem is about two times compared to normal individuals. Also, 
there is a fivefold increased risk of developing frank Type 2 Diabetes Mellitus32, 33. 
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 An Italian study based on large population, proposed that the risk of 
mortality from all causes including cardiovascular accidents, increased with the 
number of metabolic abnormalities:  
- Increased blood sugar 
- Increased blood pressure 
- High Triglycerides 
- Low HDL cholesterol, in both gender34. 
                    The Framingham offspring study reported that individuals with at 
least three risk factors associated with Metabolic syndrome, had 2.4 fold increased 
risk for Cardiovascular disorders in men and 5.9 fold in women34. 
                    Another study, Lakka et al also emphasized the importance of CVD in 
patients with MetS. The study was done in middle-aged men and they were 
followed for 11.4 years. The result is that, even in the absence of Diabetes or prior 
CVD, there is significant increased risk of CVD in the presence of MetS34. 
                   Another population based study revealed that the risk of CVD 
increases with the number of components of MetS. 
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These studies highlight two facts: 
1. The importance of creating awareness among clinicians regarding the 
strong association between MetS and CVD. 
2. The urgent need to intervene and modify the fatal cascade of events in 
patients with MetS, which has got significant impact on the society34.    
                      Even normal-weight subjects can develop Metabolic syndrome. Also 
the syndrome is not seen in all obese individuals32,17.    
 
DIAGNOSTIC CRITERIA PROPOSED FOR THE CLINICAL DIAGNOSIS 
OF THE METABOLIC SYNDROME: 
                      One of the main reasons of defining criteria for MetS is to identify 
individuals at risk of developing CVD13. 
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DIAGNOSTIC CRITERIA FOR METABOLIC SYNDROME: 
 
 
 
 
 
  MEASURES                WHO(1998)1,26 
INSULIN RESISTANCE IGT, IFG, T2DM, or Lowered insulin sensitivity 
plus any 2 of the following 
GLUCOSE IGT, IFG, OR T2DM 
BODY WEIGHT Men: waist-to-hip ratio > 0.90 
Women: waist-to-hip ratio > 0.85 and/or 
 BMI > 30 kg/m2 
BLOOD PRESSURE ≥ 140/90 mm Hg 
LIPIDS TGs ≥ 150 mg/dL and/or HDL-C < 35 mg/dL in 
men or < 39 mg/dL in women 
OTHERS Microalbuminuria: Urinary excretion rate of > 20 
mg/min or  
 Albumin : Creatinine ratio of > 30 mg/g. 
29 
 
 
 
 
 
DIAGNOSTIC CRITERIA FOR METABOLIC SYNDROME: 
 
 
 
 
 
 
 
 
 
 
  MEASURES                EGIR(1999)1 
INSULIN RESISTANCE Plasma insulin > 75th percentile plus any                   
2 of the following 
GLUCOSE IGT or IFG (but not diabetes) 
BODY WEIGHT Waist circumference ≥ 94 cm in men or ≥ 80 cm in 
women  
BLOOD PRESSURE ≥ 140/90 mm Hg or on Hypertension treatment 
LIPIDS TGs ≥ 150 mg/dL and/or HDL-C < 39 mg/dL in 
men or women 
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DIAGNOSTIC CRITERIA FOR METABOLIC SYNDROME 
 
 
 
 
  MEASURES                ATPIII (2001)1,31,23,35,36 
Any 3 of the following 5 features 
INSULIN RESISTANCE None 
GLUCOSE >110 mg/dL (includes Diabetes) 
BODY WEIGHT Waist circumference ≥ 10β cm in men or ≥ 88 cm in 
women  
BLOOD PRESSURE ≥ 1γ0/85 mm Hg 
LIPIDS TGs ≥ 150 mg/dL  
HDL-C < 40 mg/dL in men or  
       < 50 mg/dL in women 
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MEASURES AACE(2003)1 
INSULIN RESISTANCE IGT or IFG, plus any of the following based on the 
clinical judgement 
GLUCOSE IGT or IFG (but not Diabetes) 
BODY WEIGHT BMI  ≥ β5  kg/m2 
BLOOD PRESSURE ≥ 1γ0/85 mm Hg 
LIPIDS TGs ≥ 150 mg/dL and/or HDL-C < 35 mg/dL in 
men or < 39 mg/dL in women 
OTHERS Other features of Insulin Resistance (includes 
family history of Diabetes Mellitus, Polycystic 
Ovary Syndrome, Sedentary life style, advancing 
Age, and Ethnic groups susceptible to Type 2 
Diabetes Mellitus) 
DIAGNOSTIC CRITERIA FOR METABOLIC SYNDROME: 
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DIAGNOSTIC CRITERIA FOR METABOLIC SYNDROME: 
 
  
  MEASURES                IDF(2005)1,37,35,38,39 
INSULIN RESISTANCE None  
GLUCOSE ≥ 100 mg/dL (includes diabetes) 
BODY WEIGHT Increased waist circumference (population 
specific) plus any 2 of the following 
BLOOD PRESSURE ≥ 1γ0 mm Hg systolic or ≥ 85 mm Hg diastolic or 
on hypertension treatment 
LIPIDS TGs ≥ 150 mg/dL or on TGs treatment 
 HDL-C < 40 mg/dL in men or < 50 mg/dL in 
women or on HDL-C treatment 
OTHERS Other features of insulin resistance (includes 
family history of Diabetes Mellitus, Polycystic 
Ovary Syndrome , Sedentary Life Style, 
Advancing Age, and ethnic groups susceptible to 
Type 2 Diabetes Mellitus) 
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                      But, the inclusion of Abdominal adiposity in the criteria may miss 
the mortality due to CVD in non-obese individuals40.  
                     Even in patients with frank Diabetes mellitus, a subgroup of patients 
with the greatest risk of CVD was missed, using the IDF definition of Metabolic 
syndrome. The definition proposed by IDF is more restrictive as it requires the 
presence of abdominal obesity for diagnosing MetS. As a consequence, patients 
despite having Dyslipidemia and Hypertension, without abdominal obesity will 
not be diagnosed as having MetS41. 
ANTHROPOMETRIC MEASUREMENTS: 
BODY MASS INDEX (BMI): 
                    BMI is defined as the weight in kilograms divided by the height in 
meters, squared. If height cannot be measured, the Demispan or the Knee height 
can be used to calculate height with the following formulae: 
                 1. Height = 0.73 x (2 x demispan) + 0.43 
[Demispan: It is measured from the Sternal notch to the middle finger] 
            2. Height (cm) = [knee height (cm) x 1.91] – [age in years x 0.17] + 75 
For females (60 to 80 years)  
          3. Height (cm) = [knee height (cm) x 2.05] + 59.01 
For males (60 to 80 years) 
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                        BMI is increased by muscle mass and does not discriminate 
between lean body mass and fat mass. Normal BMI should be around 18.5 - 24.9 
kg/m2 .42 
WAIST CIRCUMFERENCE (WC): 
                         WC indicates the degree of abdominal obesity and is measured at 
the level of umbilicus. Hip circumference is measured at the level of the greater 
trochanters. Waist - hip ratios help to define the fat distribution whether it is 
Android or Gynoid42. 
BODY FAT DISTRIBUTION: 
                        The distribution appears to be more important compared with the 
absolute amount of excess adipose tissue, in terms of complications of obesity.  
Central obesity (increased intra-abdominal fat) is more closely associated with 
type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases, when 
compared to Generalised obesity. 
             Other names for Central obesity: 
 Abdominal obesity,  
 Visceral obesity,  
 Apple-Shaped obesity or  
 Android type of obesity;  
     Other names for Generalised obesity:  
 Pear-Shaped obesity or  
 Gynoid type  of obesity.42 
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PATHOGENESIS:   
                       A cluster of metabolic derangements are often seen associated with 
insulin resistance which are collectively referred to as Dysmetabolic syndrome or 
Syndrome X. The central abnormality predisposing to the Metabolic syndrome is 
the Insulin Resistance24.  
                   “Insulin Resistance” usually denotes resistance towards the functional 
effects of insulin in glucose uptake, metabolism, or storage43. It can be defined as 
the functional inability of insulin to exert its normal biological functions at 
concentrations, which are effective in normal individuals32, 33. 
                  It is characterized by reduced insulin mediated glucose transport and 
metabolism in Adipose tissue and Skeletal muscle and also by impaired 
suppression of glucose synthesis in the liver43,33. The resulting hyperglycemia, 
leads to the compensatory rise in secretion of Insulin32.  
                The defects are also due to impairment of insulin signalling in the target 
tissues and also from down regulation of GLUT4, the major Insulin responsive 
glucose transporter, in Adipose tissue. The entire cascade of Insulin signalling is 
affected, which includes: 
 1. Binding of insulin to its receptor, 
 2. Receptor phosphorylation, 
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 3. Activation of Tyrosine kinase activity, 
 4. Phosphorylation of insulin responsive substrate proteins43. 
                     In adipose tissue, a proposed mechanism for the signalling defect is 
excessive expression and activity of many PTPs (Protein Tyrosine Phosphatases), 
which by dephosphorylation terminates the signalling cascade, in obese 
individuals. The expression and functional activities of the following three PTPs is 
increased in Skeletal muscle and Adipose tissue of the obese people, leading to 
Insulin Resistance: 
1. PTP1B, 
2. LAR (Leukocyte Antigen-Related Phosphatase), 
3. SHP2 (Src-Homology-Phosphatase 2).43 
                      In adipose tissue, Insulin Resistance results in elevated levels of free 
fatty acids in circulation, because of impairment of suppression of lipolysis by 
Insulin. This abnormal Insulin mediated suppression of producing circulating free 
fatty acids is considered as an early manifestation in people with genetic 
predisposition for insulin resistance15.  
                    Inflammation occurs in Adipose tissue with infiltration of 
Macrophages and increase in Cytokines like TNF-alpha and IL-6, which 
antogonizes actions of Insulin. With weight loss, this inflammation is partly 
reversible. Weight loss decreases expression of genes responsible for recruitment 
of macrophages32.   
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EFFECTS OF BODY FAT DISTRIBUTION IN OBESITY: 
                                The Intra-abdominal fat drains into the Portal vein, and so directly 
reaches the liver. It is metabolically active and releases enormous amounts of Free 
Fatty Acids (FFAs), Adipokines (Tumour Necrosis Factor - Alpha, Adiponectin, 
and Resistin) and Steroid hormones. All these molecules reach the liver in high 
concentrations from the adipose tissue. The FFAs predispose to Insulin Resistance 
because they compete with glucose for oxidation in peripheral tissues as a fuel 
supply and hence to Type 2 Diabetes Mellitus42. Adipokines are structurally 
similar to Cytokines and hence their name. They exert their actions on specific 
receptors to influence Insulin sensitivity in the tissues. So, Central obesity have a 
profound influence on insulin sensitivity in the liver and affects Carbohydrate and 
Hepatic Lipid metabolism39. 
                                    In normal individuals, the origin of majority of fatty acids reaching 
the liver is from lipolysis of the subcutaneous adipose tissue. Only 5-10% comes 
from the visceral adipose depot, but in individuals with visceral obesity, it is 
increased to 30%. Normally, less than 5% of fatty acids come from the denovo 
synthesis by liver, and this is also significantly increased in fatty liver patients32.   
                                    The high lipolytic rate of the intra abdominal visceral fat (Omental 
and Mesenteric), contributes to approximately 26% of the FFA release from the 
upper body. It is out of proportion to the actual mass. This in turn, increases the 
supply of substrates for gluconeogenesis, contributing to the failure of suppression  
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          of gluconeogenesis by insulin, in turn leading to excessive Hepatic glucose 
production. Also, the FFAs in Liver affect the Insulin mediated disposal of glucose 
to the peripheral tissues, mainly the skeletal muscle. The increased FFAs in the 
liver also contribute to peripheral Hyperinsulinemia by reducing the extraction of 
Insulin into the Liver tissue44.  
                                Weight loss rapidly reduces Hepatic fat content and improves Insulin 
sensitivity32. The presence of enlarged adipocytes in the visceral adipose tissue is a 
predictor of upper body obesity and its complications. The enlargement of the 
adipocytes can also be a consequence of the resistance to insulin mediated 
suppression of lipolysis44. Patients with abdominal obesity have an insulin-
resistant type of fibres in their skeletal muscle32.  
                              Although Obesity is clearly associated with CVD, it is mainly 
mediated by other cardiovascular risk factors like hypertension, diabetes and lipid 
profile imbalances45.  
EFFECTS OF FREE FATTY ACIDS: 
1. Inhibits Insulin mediated glucose uptake. 
2. Impairs Insulin mediated suppression of endogenous glucose production. 
3. Impairs glucose mediated suppression of endogenous glucose production. 
4. Stimulates short-term Insulin secretion. 
5. Inhibits long-term Insulin secretion, possibly due to Islet toxicity. 
6. Reduces Hepatic clearance of Insulin. 
7. Increases the production of VLDL triglycerides. 44 
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HEPATIC INSULIN RESISTANCE : 
                      Normally, Insulin action of lowering plasma glucose level is by  
1. Suppression of hepatic gluconeogenesis  
2. Decreasing uptake of amino acids and free fatty acids from muscle and 
adipose tissue to liver and  
3. Favouring glucose uptake by skeletal muscle and adipose tissue.    
                       Compared to adipose tissue, the Insulin mediated uptake of glucose 
by muscle is ten times more. This is because of the greater muscle mass.15 For 
Insulin to effectively suppress gluconeogenesis in the liver; normal Insulin 
responsiveness is required at the Adipocytes. So, suppression of endogenous 
glucose production is in part depends on the ability of Insulin to decrease the 
levels of FFAs. 15              
INSULIN RESISTANCE AND DYSLIPIDEMIA: 
                    The risk factor for Coronary artery disease in the syndrome is the 
existing Dyslipidemia. The main cause for Dyslipidemia is excessive synthesis of 
apolipoprotein B containing VLDL (very low density lipoprotein) particles. 24 
                  The physiological function of Insulin is to suppress VLDL production, 
in particular Apolipoprotein B particles, in the liver, by the following mechanisms: 
1. Decreases FFA availability by inhibiting lipolysis in adipose tissue. 
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2. Direct hepatic effect - by affecting the assembly and hence the synthesis of 
VLDL.32, 33  
                      In Metabolic syndrome, the synthesis of apolipoprotein B by the 
liver is increased. It is also increased by the occurrence of large quantities FFAs in 
the portal circulation, which are released from the visceral adipose tissue as a 
consequence of increased lipolysis. Insulin and FFAs also mediate the transfer of 
lipids to apolipoprotein B, by increasing the levels of Microsomal Triglyceride 
Transfer Protein and moreover, they reduce the degradation of apolipoprotein B by 
Ubiquitination-dependant pathway. 24 
                      In skeletal muscle, Insulin resistance is directly related to the intra-
myocellular Triglyceride concentration29.  
                                    As a consequence of the VLDL triglyceride overproduction, there 
occurs exchange of VLDL triglyceride to HDL (High Density Lipoprotein) – 
cholesterol esters by the action of Cholesterol Ester Transfer Protein24. 
                                    The triglyceride-rich HDL molecules are good substrates for 
degradation by Hepatic Lipase32. Hepatic lipase hydrolyze these HDL molecules, 
to produce small HDL molecules, which are easily degraded by the kidney leading 
to low levels of serum HDL24.  
                     The VLDL triglycerides are also exchanged for LDL – cholesterol 
esters by the same Cholesterol Ester Transfer Protein. Again these triglycerides are 
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hydrolyzed by the hepatic lipase to produce small, dense LDL particles, which are 
commonly seen in patients with Insulin Resistance24. The small dense LDL 
particles are highly atherogenic, predisposing the individuals to cardiovascular 
complications32. 
                        The major risk factors for developing atherosclerosis include the 
components of MetS like Dyslipidemia, hypertension, diabetes mellitus and 
smoking. The normal function of the vascular endothelium is altered leading to 
subintimal aggregation of fat, smooth muscle cells and fibroblasts to form 
atherosclerotic plaque46.  
                      So, the patients with metabolic syndrome are subjected to aggressive 
treatment with lipid lowering agents to prevent cardiovascular complications24.  
INSULIN RESISTANCE AND HYPERTENSION: 
                        The concurrence of Hypertension and Insulin resistance doubles the 
risk of Cardiovascular complications. In normal individuals, Insulin induces the 
endothelial cells to increase the production of Nitric Oxide, a potent vasodilator24. 
Insulin resistance thus causes defect in vasodilatation and sodium absorption by 
the kidney is preserved, leading on to hypertension17. Increased plasma FFAs also 
contributes to the defect. Insulin activates the sympathetic nervous system and also 
causes expansion of plasma volume by promoting salt and water reabsorption by 
the kidney tubules; and so Hyper insulinemia contributes to Hypertension24.  
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                      Conversely, Hypertension also contributes to Insulin resistance. The 
defect in vasodilatation reduces the surface area of the vessels perfusing the 
skeletal muscles, thereby reducing glucose uptake24.  
CENTRAL CONTROL OF GLUCOSE METABOLISM: 
                                    The hypothalamus and certain other regions of the brain are 
capable of sensing metabolic requirements and causing alterations in the 
metabolism as needed. For example, the fatty acids which are taken up by the 
Mediobasal Hypothalamus alter the feeding behaviour and reduce glucose 
production by the Liver24. The receptors for Insulin are seen widely in the brain 
tissue. Insulin regulates satiety by centrally suppressing appetite. The 
Hypothalamic insulin receptor is very important in regulating hepatic glucose 
metabolism, because the central inhibition of insulin also decreases the effect of 
exogenously administered Insulin in suppressing Hepatic glucose production15.  
GENETIC CAUSES OF INSULIN RESISTANCE: 
                                The high prevalence of Insulin resistance in certain populations, 
suggests a strong genetic basis, in addition to the westernized life style with high 
calorie intake and being sedentary. Between monozygotic twins, there is nearly 
100% concordance in diagnosis of type 2 diabetes mellitus, but only 20% between 
dizygotic twins15.  
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EXTREME INSULIN RESISTANCE: 
                                  Extreme Insulin resistance is due to some rare mutations in genes 
associated with Insulin action. Associated conditions include Hyper Insulinemia, 
Dyslipidemia, Hypertension, and Impaired Glucose Tolerance. The skin lesion, 
Acanthosis Nigricans is characteristic of Insulin resistance. It occurs in the 
flexures and neck, as a papillomatous pigmented hyperkeratotic lesion. Women 
with Extreme Insulin Resistance are manifested with Hyper Androgenism, 
Hirsuitism and Menstrual disorders15. 
INSULIN RECEPTOR MUTATIONS: 
                                 More than 100 mutations of Insulin receptor gene are known. The 
complete absence of Insulin receptors have also been reported15. 
i. LEPRECHAUNISM: The most severe form of the syndromes with severe 
Insulin resistance. It is characterised by Intrauterine Growth Retardation, 
prominent eyes, upturned nostrils, thick lips, posteriorly rotated low set 
ears, and thick skin lacking subcutaneous fat tissue. Individuals succumb 
within one year of age15. 
ii. RABSON-MENDENHALL SYNDROME: It is a milder syndrome with 
incomplete absence of Insulin receptors. Patients have life expectancy up to 
15 years of age and characterised by growth retardation and several 
dysmorphic features including gingival hyperplasia and dysplastic teeth. 
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Due to inappropriately elevated fasting insulin levels, the affected children 
exhibits fasting hypoglycemia, but they have post prandial hyperglycemia15. 
iii. TYPE A INSULIN RESISTANCE: It is the mildest form of Insulin 
receptor gene mutations. It constitutes a triad of Insulin Resistance, 
Hyperandrogenism (in females) and Acanthosis Nigricans. The patients 
have mostly a heterozygous mutation often in the receptor’s tyrosine kinase 
domain. Most of the people do not develop diabetes. Patients with 
homozygous alleles are prone to develop frank diabetes in late childhood or 
adolescence15. 
iv. INSULIN MEDIATED PSEUDO ACROMEGALY: A syndrome of 
severe Insulin resistance associated with pathologic tissue growth similar to 
that of Acromegaly, but there is no elevation of Growth hormone and IGF-
1. The defect lies in the post receptor signalling of Insulin. The severe 
Hyperinsulinemia activates the mitogenic signalling pathways, which are 
intact resulting in Acromegaloid tissue growth15. 
v. MUTATIONS IN THE PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTOR γ (PPARγ): This receptor has a vital role 
both in differentiation of adipocytes and Insulin action. Heterozygous loss 
of function type of mutations has been reported in the ligand-binding 
domain of the receptor. The defect is characterised by features of severe 
Insulin Resistance, partial lipodystrophy of limbs and buttocks, sparing the 
face and central abdominal adipose tissue. The inability to trap the free fatty 
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acids after a meal, by the subcutaneous adipose tissue results in 
lipodystrophy15. 
LIPODYSTROPHY:  
                            It includes a group of disorders which are characterised by complete or 
partial absence of adipose tissue and Insulin resistance. 
1. FAMILIAL PARTIAL LIPODYSTROPHY: The patients appear normal 
at birth, but after puberty they tend to lose the subcutaneous tissue from the 
gluteal region and extremities. So, the muscles look prominent in these 
areas. Fat deposition is increased in the face, neck, axilla, abdominal cavity 
and labia majora. Imaging studies show complete absence of adipose tissue 
in the affected regions. The adipose tissue is preserved in intra-thoracic, 
intra-abdominal, inter-muscular and bone marrow. Inter-muscular fat is 
excessively accumulated. Several mutations were identified by genetic 
studies in these patients, in the gene LMNA, which codes for Lamin A and 
Lamin C. These are structural proteins present in the nuclear membranes of 
myocytes and adipocytes and aid in DNA replication in these cells15.  
2. CONGENITAL GENERALISED LIPODYSTROPHY: This disorder is 
characterised by Insulin resistance and a complete absence of adipose tissue 
from birth. The patients show features of Insulin resistance along with 
Muscular Hypertrophy, Hypertrophic Cardiomyopathy and Hepatomegaly 
collectively referred to as THE ANABOLIC SYNDROME. Death occurs 
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usually in early childhood due to cardiac complications. The mutations 
associated with this syndrome are found in two different genes on different 
chromosomes:  
i. AGPAT2 gene coding for the enzyme, 1-acyl glycerol-3-
phosphate-O-acyl transferase 
ii. BSCL2 gene encoding a protein called, SEIPIN, whose function is 
not known. 
       The enzyme, 1-Acyl Glycerol-3-Phosphate-O-Acyl Transferase 
catalyzes a key step in triacylglycerol synthesis. It helps in the formation of 
Phosphatidic acid by acylation of Lyso-phosphatidic acid. So, if this gene gets 
mutated, triacyl glycerol synthesis is affected. Hence, storage of triacylglycerol in 
adipose tissue is not possible leading to Congenital generalised lipodystrophy15.  
 
COMMON POLYMORPHISMS CAUSING INSULIN RESISTANCE: 
1. P85 subunit of PI3K (1-Phosphatidyl Inositol 3-Kinase) codon 326 
Methionine  Valine; This resulted in reduced insulin sensitivity. 
2. IRS-1-G972R polymorphism. This results in reduced binding between IRS-
1 and the p85 subunit of PI3K and thereby reduces IRS-1 mediated PI3K 
functional activity. 
3. Gene 3q27 coding for Adiponectin, resulting in decreased levels of 
circulating Adiponectin.15 
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                        Adiponectin is synthesized in Liver. Its hormonal action in liver is 
to decrease inflammation and to increase sensitization to Insulin, thereby 
decreasing Hepatic lipid content. Serum levels of Adiponectin is considerably 
lowered in patients with Metabolic syndrome, compared to normal individuals.32 
INSULIN SECRETION IN OBESITY AND INSULIN RESISTANCE: 
                    To maintain glucose homeostasis, normal Insulin secretion is 
essential. So, in patients with obesity and Insulin resistance, as a compensatory 
mechanism, hyper-secretion of insulin occurs. The blood glucose level is 
determined by the ability of the pancreatic beta cells; the patient may be normo-
glycemic or may develop impaired glucose tolerance or Diabetes. The hyper 
secretion of Insulin, even in the presence of normo-glycemia, occurs due to 
increase in sensitivity of beta cells to glucose47. This increase in sensitivity is due 
to two factors: 
1. Increased beta cell mass of pancreas. 
2. Increased expression of Hexokinase compared to Glucokinase expression in 
the beta cells47. 
                       The Michaelis constant(Km) of Hexokinase is much lower than that 
of Glucokinase for glucose; so, the activity of increased Hexokinase leads to 
increased Insulin secretion, over a wide range of blood glucose concentrations. 
This causes a shift to left in the glucose-Insulin dose response curve. This hyper-
insulinemia is due to both increased Insulin secretion and also decreased Insulin 
48 
 
clearance. The rate of Insulin secretion is three to four times higher in obese 
people and it has a strong correlation with the Body mass index. 50% of the total 
Insulin produced daily comes from the basal secretion; and Insulin secretory 
pulses occur every 2 hours. This is similar to the normal temporal pattern of 
Insulin secretion found in non-obese individuals. The difference lies in the 
amplitude of the post prandial pulses, which is much higher in obese people47.    
                      In Impaired glucose tolerance, this temporal pattern of Insulin 
secretion is altered. The impairment lies in the capability of beta cells in sensing 
and responding to the changes in the plasma glucose levels. This altered temporal 
pattern of Insulin secretion is considered to be an early manifestation of 
dysfunction of beta cells, leading on to Type 2 Diabetes Mellitus47.    
                    In Type 2 Diabetes Mellitus, again in response to insulin resistance, 
hyperinsulinemia occurs. But the degree of hyperinsulinemia is low compared to 
the plasma glucose levels. Abnormality of beta cells lies in the first phase of 
insulin secretion47. 
MEDICAL CONDITIONS CAUSING INSULIN RESISTANCE: 
1.  Auto-immune disorders, including Systemic Lupus Erythematosus, due to 
the presence of antibodies against insulin receptor. 
2. Renal failure and Uremia, accumulation of Uremic toxins, raised levels of 
Growth Hormone and Glucagon and Metabolic Acidosis. 
3. Hepatic Cirrhosis, due to elevation in circulating FFAs.  
49 
 
4. Familial Hemochromatosis, where Insulin secretion and Insulin action are 
related to the extent of hepatic iron accumulation. 
5. Thalassemia major, due to transfusion-induced iron overload. 
6. Many types of cancer - Gastrointestinal and Pancreatic tumours, due to 
inhibition of Insulin action by cytokines, TNF-alpha and IL-6.15 
NUTRIENT EXCESS AND  ITS EFFECTS ON SYSTEMIC INSULIN 
ACTION: 
                    Our body cells have the capability to sense the availability of 
nutrients, and accordingly regulate insulin signalling or glucose transport or 
both15.  
1.  GLUCOSE TOXICITY: Chronic hyperglycemia has inhibitory action on insulin 
secretion and action. The proposed mechanism of insulin resistance mediated by 
hyperglycemia includes: 
a. Down regulation of glucose transport system 
b. Defect in Insulin mediated synthesis of glycogen15. 
HEXOSAMINE BIOSYNTHETIC PATHWAY: (HBP pathway) 
                  The entry of glucose into this pathway is essential for hyperglycemia 
induced Insulin resistance. 
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                     Normally, only 1 to 3% of glucose, which gets converted to fructose-
6-phosphate, enters this pathway to synthesize Uridine diphosphate-N-acetyl 
glucosamine (UDP-N-GlcNac). UDP-N-GlcNac is the main substrate for 
glycosylation of proteins and its intracellular concentration is nutritionally 
regulated. The activities of many enzymes and transcription factors are regulated 
by the glycosylation of their serine or threonine residues. In hyperglycemia, when 
more glucose enters the pathway, glucose will not be available for glycogen 
synthesis and glycolysis15.  
       HEXOSAMINE 
      BIOSYNTHETIC                                         PROTEIN 
        PATHWAY                                               KINASE C 
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                    The first and rate-limiting step of this pathway is catalyzed by the 
enzyme Glutamine: Fructose-6-phosphate Amidotransferase (GFAT). Glutamine 
is required for this rate limiting step of the pathway and hence glutamine 
analogues are being used to hinder the pathway and hence insulin resistance 
mediated by hyperglycemia15. 
2. LIPID TOXICITY: Persistent increase in circulating free fatty acids is a 
hallmark of Insulin resistance15.  
IMPACT OF FREE FATTY ACIDS ON INSULIN: 
a. SKELETAL MUSCLE: The main effect is inadequate suppression of oxidation 
of fatty acids by Insulin. An increase in the availability of free fatty acids leads to 
increased in the mitochondrial Acetyl CoA/CoA ratio and NADH/NAD+ ratio. 
This in turn inactivates the enzyme, Pyruvate dehydrogenase and 
Phosphofructokinase by feedback mechanism. So, the intracellular concentrations 
of glucose-6-phosphate gets elevated which again by feedback mechanism causes 
inhibition of Hexokinase activity, which further leads to increased intracellular 
glucose concentration and reduced glucose uptake15.  
                       FFA down regulates Insulin signalling in skeletal muscles15. Also, 
the raised FFA levels increases the phosphorylation of serine/threonine residues on 
the insulin receptor substrates, IRS-1 and IRS-2, thereby reducing IRS mediated 
glucose transport15. 
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                   FFAs inhibit Fructose-6-Phosphate from entering into glycolytic 
pathway, shunting it into the HBP pathway forming increased amount of 
glucosamine-6-phosphate15. 
b. LIVER:   
                     The extent of hepatic Insulin resistance correlates well with the fat 
content of Liver32. As already mentioned, the FFAs increases endogenous 
production of glucose by inhibiting Insulin mediated suppression of Hepatic 
gluconeogenesis. The FFAs increases the activity of Hepatic Glucose-6-
phosphatase more compared to the increase in the activity of Glucokinase, thus 
increasing the glucose output from liver. Fatty acid oxidation is inhibited by 
suppressing the enzyme, CPT-1, which in turn is caused by the elevation of 
malonyl CoA. This favours fatty acid esterification resulting in increased synthesis 
of Triglycerides and VLDL, contributing to the dyslipidemia of Insulin 
resistance15. 
OXIDATIVE STRESS: 
                     Oxidative stress decreases Insulin responsiveness and impairs Insulin 
signalling. Signalling pathways involving nuclear factor-KB, p38 MAPK and 
NH2-Terminal Jun Kinases and some protein kinases, which usually undergo 
stress induced activation are enhanced by FFAs and glucose, leading to Impaired 
Insulin Secretion and also Insulin Resistance. 15  
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                    Increased availability of nutrients leads to consequent increase in 
reactive oxygen species (ROS). The ROS activates isoforms of Protein kinase C, 
leading to synthesis of AGEs (Advanced Glycation End products). 15 
AGING: 
                    With advancing age, increased incidence of Insulin Resistance is 
seen15. In most populations in the world, the age dependency for the prevalence of 
the syndrome is found to be true17.  
The causes are:  
1. Increased fat depot, in particular visceral fat. 
2. Increased cytokines levels in circulation. 
3. Increased accumulation of Triglycerides in the cells. 
4. Decline in Mitochondrial functions mainly Oxidative Phosphorylation. 
5. Resistance to effects of Leptin on fat distribution leading to increased lipid 
accumulation in tissues.15 
            So, the development of central factor of Metabolic Syndrome, the Insulin 
Resistance depends on a complex interplay consisting of Genes, Obesity and 
Environment, which in turn includes nutritional factors, hormones and finally 
advancing age.15 
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METABOLIC SYNDROME AND CVD: 
                      Individuals with MetS are at increased risk of CVD and total 
mortality, especially in men aged 45 years and women aged 55 years26,48. And 
those with frank diabetes or prior CVD are at a even higher risk26. Simultaneous 
occurrence of Hypertension and impaired glucose metabolism has the highest risk 
and accounted for the most of the deaths36. Patients with manifestations of 
atherosclerosis and MetS are at increased risk of CVD and total mortality, 
irrespective of the presence or absence of Type 2 Diabetes mellitus38. 
                    In Coronary Heart Disease patients, Metabolic syndrome prevails in 
almost 50%. With proper Cardiac rehabilitation and life style modifications, the  
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prevalence of the syndrome can be markedly lowered37. Both overweight and non-
overweight individuals with metabolic risk factors should be targeted to bring 
down the burden due to CVD in general population35. 
INTER-RELATION AND OVERLAP OF METABOLIC SYNDROME 
WITH INSULIN RESISTANCE, PRE-DIABETES AND TYPE 2 
DIABETES11: 
 
METABOLIC SYNDROME 
 
INSULIN RESISTANCE 
  PRE-DIABETES (75% MetS) 
 `TYPE 2 DIABETES(86%MetS) 
 
CARDIOVASCULAR DISEASE 
 
                          Population based preventive measures should be undertaken by 
increasing the awareness of the association of risk factors, in particular for South 
Asians18. Epidemiologists from India and international agencies like WHO (World 
Health Organization) proposed the rapidly rising impact of CVD as a potential 
alarm for the past 15 years. The estimate is about 2.6 million among Indians, by 
2020, CVD being the foremost cause of morbidity and mortality49.  
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FGF-19 (FIBROBLAST GROWTH FACTOR 19) 
                      A large number of signals getting released from enterocytes are 
known to regulate feeding, blood glucose and induce satiety. Some of them 
include Cholecystokinin, Ghrelin, peptide YY, Oxyntomodulin and Glucagon-like 
peptide. Recently, FGF 19 is being added to the list of Gastrointestinal hormones 
regulating metabolism.50  
                   FGF 19 is a unique member of the Fibroblast Growth Factor family.51 
 The members of the family are known to be involved in: 
 Embryonic development 
 Cell growth and survival 
 Morphogenesis 
 Tissue repair - Wound healing 
 Tumour growth and Angiogenesis51,52. 
             The FGF signaling pathway is a ubiquitous micro environmental 
regulator of adult homeostasis and cell to cell communication4.      
FGFRS (FIBROBLAST GROWTH FACTOR RECEPTORS): 
                    The FGF family members exert their actions by binding to receptors 
on the cell surface, referred to as FGFRs51. 
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                    After binding, dimerisation of receptors occurs followed by activation 
of Tyrosine kinases. They are encoded by four different genes, Fgfr1 to Fgfr453. 
                   Initially FGF proteins were characterized by their ability to promote 
proliferation of fibroblasts. FGFRs 1, 2 and 3 mediated this mitogenic activity. 
FGFR4 was identified then to possess the ability to bind FGFs, but lacks 
mitogenic proliferation54. 
                    FGFR signalling plays a major role in regulating glucose homeostasis 
and energy balance55,56. 
        Their interactions with FGFRs is promoted by their high affinity to 
Heparan sulphate, a glycosaminoglycan found on the cell surface.51 
        The structure of FGFRs1-4 constitutes three domains each: 
1) An extracellular ligand binding domain, 
2) A single transmembrane domain, 
3) An intracellular Tyrosine kinase domain.5   
FGF FAMILY: 
                    The FGF family constitutes about 22 members, including FGF 1 to 
FGF 23.  FGF 15 is not found in Humans. They are further divided into three 
subfamilies: 
1. Canonical 
2. Intra cellular 
3. Hormone-like.57 
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                   The canonical FGFs have binding sites for Heparin for stable 
interactions with FGFRs. Hormone like FGFs have reduced affinity to heparin, 
and hence they are endocrine in function. This property of hormone-like FGFs is 
acquired during evolution57.  Instead they require klotho proteins, which acts as a 
co-receptor/co-factors to facilitate their binding with their cognate receptors in the 
target tissues57,58.  
                        FGF 19 subfamily consists of FGF 19, FGF 21 and FGF 2358,59 . 
They are involved in regulation of bile acid, glucose, lipid, phosphate, energy and 
vitamin D homeostasis, by acting in an endocrine fashion. They require interaction 
of α or ȕ klotho proteins58. 
                       The extremely low affinity of FGF 19 subfamily to Heparan sulfate, 
permits their circulation to reach distant tissues, as a hormone, to bind with FGFR 
and Klotho proteins.60 
                        ȕ klotho protein is expressed in muscle, adipose tissue, liver and 
pancreas60. ȕ klotho protein mediates the tissue responsiveness to FGF 19 and 
their levels are found to be low in adipose tissue in individuals with Obesity.61 
                      To interact with these cofactors, amino acid sequences present in the 
C-terminal end is important. This C-terminal ȕklotho binding domain is absent in 
Canonical FGFs, which do not require interaction with the co-receptors. The C-
terminal tail is proposed to be acquired during evolution, as a compensatory 
mechanism for its weakened affinity towards Heparan sulfate.62 
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                     Human FGFs comprises of about 150 to 300 amino acids. A core 
residue with 120 amino acids is conserved among the family members. The 
members have 30 to 60% identity among themselves57. Based on the similarities in 
sequences and functions, human FGFs can be classified in to seven subfamilies.5 
 
FGF FAMILY MEMBERS: 
 FGF1 subfamily 
                      - FGF1 (Acidic FGF) 
                      - FGF2 (Basic FGF) 
 FGF4 subfamily 
- FGF4 
- FGF5 
- FGF6 
 FGF7 subfamily 
- FGF3 
- FGF7 
- FGF10 
- FGF22 
 FGF8 subfamily 
- FGF8 
- FGF17 
- FGF18 
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 FGF9 subfamily 
- FGF9 
- FGF16 
- FGF20 
 FGF11 subfamily 
- FGF11(FHF 3) 
- FGF12 (FHF 1) 
- FGF13 (FHF 2) 
- FGF14 (FHF 4) 
 FGF19 subfamily 
- FGF19 
- FGF21 
- FGF23.63 
 
FGF 19:  
                       Human FGF 19 is a 24 kD protein.64 Following a meal, FGF 19 is 
secreted from the ileum, binds to FGFR4 and ȕklotho protein, and mediates 
postprandial responses65. FGF 19 from ileum reaches the hepatocytes through 
portal circulation, to exert its effects, acting as a entero-hepatic signal66,7,67.   
                     The complex triggers the activation of cellular kinases, namely 
ERK(Extracellular signal Regulated protein Kinase) and GSK, inhibiting Hepatic  
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SITE OF FGF 19 SYNTHESIS 
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synthesis of bile acids and glucose respectively. Synthesis of Glycogen and protein 
is stimulated.65, 8 
                      Bile acid not only induces FGF 19 secretion from the intestine; they 
also activate the FGF 19/FGFR4 signalling in hepatocytes. This helps in inhibition 
of bile acid synthesis and also prevents excess accumulation of toxic bile contents 
in the Liver.66   
                     FGF 19 is unique in the way that: 
1. It has lower affinity towards Heparan sulphate; instead they use 
transmembrane receptors called as ȕ-klotho.51    
2. Unlike other FGFs, it acts specifically on FGFR4 alone, which has no 
mitogenic response51,54,63.  
3. It performs endocrine functions in addition to its autocrine and paracrine 
functions. 51 
 Endocrine functions - Bile acid, Glucose and Lipid Metabolism.  
 Paracrine functions - Embryogenesis, Cell Growth and Differentiation, and 
Angiogenesis. 
 Autocrine functions - Promotes proliferation and invasion of cancerous 
tissues.51 
                        Due to its reduced affinity towards Heparan sulfate, it is loosely 
held on the cellular membrane and gets detached from the extra cellular matrix, 
escaping into circulation, facilitating the endocrine actions51,68.  
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                      FGF 19 transcripts are seen in many tissues like Brain, Skin, Gall 
Bladder, Kidney, Umbilical cord, Cartilage and Intestine, but it is primarily 
expressed in Ileum6,51,69,70. Even though it is secreted in the ileum, the specific 
FGFR4 receptors occurs in Liver in large numbers51,52. This contributes to the 
metabolic effects of    FGF 19. 
                    FGF 19 is a postprandial enterokine, derived from Ileum that governs 
metabolic processes71.FGF 19 is a peptide hormone consisting of 216 amino 
acids9. It was originally identified in chick embryos as a promoting factor in inner 
ear development2.  
                  FGF 19 consists of two disulfide bonds. The disulfide bonds are 
important for stability, protein folding and activity and are more common in 
mammalian proteins72. The intra-molecular disulfide bond contributes to their 
plasma stability and facilitates them to function as hormones on distant tissues58.  
                      FGF 19 is stable for up to ten minutes in blood and brain. Entry of 
FGF 19 in to brain depends on its serum concentration. In the basal state, the role 
of FGF 19 in regulating metabolism dominates its action on the central nervous 
system. Excretion of FGF 19 is by the Kidneys. In end stage renal disease, FGF 19 
concentration is found to be elevated in the blood.73    
                      Bile acids acts as the ligand for FXR, thus the receptors are referred 
to as the “bile acid sensor”. FXR in turn increases the expression of FGF 19 from 
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the enterocytes9. So, in response to food intake, concentration of serum FGF 19 is 
increased8. 
                      Bile salts negatively regulate their own production.74,67 They help in 
digestion and absorption of dietary lipids in the proximal parts of small intestine. 
After fulfilling their function, bile salts reach the terminal ileum and activate FXR 
to secrete FGF 1974. The secretion of FGF 19 represents a transition between the 
fed and the fasting states, acting as a late postprandial signal6. 
                        FXR is capable of controlling various metabolic pathways. They 
regulate synthesis of bile acids, conjugation and transport, upon activation by bile 
acids and also different aspects of Carbohydrate and lipid metabolism3.   
                      The functional FGF receptor complex comprises of: 
 Trans membrane tyrosine kinase 
 Heparan sulfate  
 Activating FGF.52, 5 
FIBROBLAST HOMOLOGOUS FACTORS(FHFs): 
                      These factors have sequence and structural similarity with FGFs, 
including high affinity to Heparin, but cannot bind and activate FGFRs. The intra-
cellular domains of the voltage-gated sodium channels are the main target for 
FHFs. In humans, mutations in FHFs resulted in Cerebellar Ataxia.70    
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MODE OF ACTIONS OF FGF 19 FAMILY MEMBERS63: 
 
             FGF 19                                     FGF 21                                   FGF23 
 
                                               ADIPOSE             
LIVER                                   TISSUE                                    KIDNEY 
 
 
 
 
 
   BILE ACID                       CARBOHYDRATE &               PHOSPHATE & 
  METABOLISM               LIPID METABOLISM           VITD METABOLISM 
 
 
 
ROLE OF FGF 19 IN BODY METABOLISM: 
1. BILE ACID METABOLISM: 
                      Bile acid synthesis forms a major pathway for catabolism of cholesterol 
in humans. Cholesterol is hydroxylated at position 7 by the enzyme cholesterol 7 α 
hydroxylase (Cyp7a1) in Endoplasmic reticulum.  This is the rate limiting step in bile 
acid synthesis. This step is under feedback inhibition51. 
 
 
FGFR4 βKLOTHO FGFR1c FGFR1c βKLOTHO KLOTHO 
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THE PHYSIOLOGY OF FGF 19: 
 
                                                       INTESTINE 
 
 
 
 
 
 
 
 LIVER 
 
 
 
 
 
                       In the intestine, the bile acids activate the nuclear receptor in the 
enterocytes, called the Farnesoid X receptor (FXR)51,75. Then, FXR increases the 
secretion of FGF 19 by the ileum, FGF 19 binds to FGFR4 in liver and inhibits 
transcription of Cyp7a1 gene, thereby repressing bile acid synthesis,51,6. This 
BILE ACID FXR  FGF 19 
 LIPOLYSIS 
 LIPOGENESIS 
  ACC2,    SCD CYP7A1 
  BILE ACID 
SYNTHESIS 
69 
 
feedback inhibition is also mediated by increased expression of SHP-1(Small 
Heterodimer Partner-1), a member of the nuclear receptor family. This in turn 
inhibits the expression  of Cyp7a151,76. Increased flux of bile acids is followed by a 
peak in serum FGF 19 levels in about 90 to 180 minutes after a meal. FGF 19 
deficiency is an important factor causing bile acid malabsorption.  It can be treated 
with FXR agonists, which in turn stimulates FGF 19 secretion, which covers for 
FGF 19 deficiency and bile acid diarrhoea can be prevented. But the property of 
tumorigenesis of FGF 19 limits the use of such treatments leading to increased 
FGF 19 levels in serum than the physiological level51. But, now M70, a non-
tumorigenic variant has been engineered, retaining all other biological functions is 
available51,64. So the hopes of using FGF 19 in treatment of metabolic diseases 
have increased tremendously. 
2. GLUCOSE AND PROTEIN METABOLISM: 
                     FGF 19 is known to lower blood glucose levels. It promotes glycogen 
synthesis and protein synthesis in muscle and liver, similar to Insulin51,71,77.  
                    Glycogen synthase is the rate limiting enzyme of the pathway of 
Glycogen synthesis. It is active in its dephosphorylated state and becomes inactive 
when phosphorylated. Glycogen synthase kinase γα (GSK γα) and GSK γȕ are the 
enzymes responsible for phosphorylation of Glycogen synthase. These enzymes, 
themselves become inactive on phosphorylation. FGF 19 promotes activation of 
Glycogen synthase by phosphorylating these enzymes. Thus Glycogen synthesis is 
favoured51. 
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                  The Eukaryotic Initiation Factor 4F (eIF4F) complex mediates protein 
synthesis. It is responsible for binding of mRNA to the ribosomes and hence 
mediates initiation of translation. The complex consists of two major proteins: 
 eIF4B 
 eIF4E 
                   FGF 19 phosphorylates these proteins and activates them aiding in 
initiating translation. FGF 19 also increases the phosphorylation of rpS6 
(ribosomal subunit protein S6), which in turn lead to increase in global protein 
synthesis51. 
                     Hence the actions of FGF 19 is similar to Insulin in phosphorylating 
the eukaryotic initiation factors and the ribosomal protein S6, but differs in the 
further pathway downstream. Insulin acts through the mTOR pathway, by 
increasing the phosphorylation of protein kinases AKT and p70 S6 kinase. In 
contrast, FGF 19 acts via phosphorylation of p90 S6 kinase by activating ERK1 
and ERK2. So, FGF 19 acts in a parallel fashion but independent of the pathway 
of Insulin in governing protein synthesis in Liver51.  
3. LIPID METABOLISM: 
                       FGF 19 down-regulates the enzyme, Acetyl CoA Carboxylase 
2(ACC2), and inhibits conversion of Acetyl CoA to Malonyl CoA. Malonyl CoA 
is a repressor of the enzyme, Carnitine Palmitoyl Transferase 1(CPT1), which 
initiates Fatty acid oxidation. So, by reducing the activity of ACC2, FGF 19 
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induces Fatty acid oxidation. FGF 19 also down-regulates the enzyme Stearoyl 
CoA desaturase, which in involved in Lipogenesis70.   
                         FGF 19 by increasing the oxidation of fatty acids, reduces 
Triglyceride concentration9. Unlike Insulin which favours lipogenesis, FGF 19 
inhibits fatty acid synthesis51,71 and decreases the expression of enzymes of 
lipogenesis in liver cells2.  
4. MITOGENIC ROLE: 
              Induction of tumour and cancer: FGF 19 has potent mitogenic 
activity. The FGFR-FGF 19 signalling is found to play a major role in 
development and progression of HCC (Hepato Cellular Carcinoma). FGF 19 is 
over expressed in cancerous liver. Treatment with recombinant FGF 19 resulted in 
increased proliferation and invasion of the cancerous tissue and also inhibits 
Apoptosis in cancer cells51.  
5. ANGIOGENESIS:  
 FGF 19 acts s a major growth factor is expressed during development of 
retina. In lens cells, it is necessary for differentiation of lens fibres and its 
survival.  
 It is involved in patterning of retina in the nasal-temporal region and in 
guiding the axons of retinal ganglion cells. 
 It regulates cell division. 
 It also plays a role in the development of forebrain and is significantly 
expressed in fetal brain tissue. 
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 It helps in development of embryonic spinal cord. 
 It is critical for development of ventral regions of diencephalon and 
telencephalon. 
    It is involved in the specification of oligo dendrocytes and GABAergic 
interneurons in the ventral region of diencephalon and telencephalon. 
    Inhibition of functions of FGF 19 affects brain development during mid-
segmentation stages, resulting in reduction in the size of cerebellum, 
forebrain and midbrain. 
    FGF 19 helps in development of inner ear, by aiding in patterning of the 
neuro ectoderm.51 
                          So, FGF 19 acts as a multifunctional regulator, influencing many 
physiological events. 
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AIMS AND OBJECTIVES 
 
Aim of the study: 
                 To measure serum Fibroblast Growth Factor 19 in patients with 
Metabolic syndrome and to compare the serum level of FGF 19 with healthy 
individuals. 
Objective of the study: 
                To analyze the correlation between serum FGF 19 and the components 
of Metabolic syndrome. 
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MATERIALS AND METHODS 
      The study was conducted at Thanjavur Medical College, Thanjavur, 
after being approved by the Ethical committee. Participants of the study group 
were selected from the Outpatient Department of Medicine. 
                The study included 50 patients with Metabolic syndrome (25 males, 25 
females) and 50 age and sex matched healthy controls (25 males, 25 females), in 
the age group of 20-70 years. Informed consent was obtained from all the 
participants. 
 
INCLUSION CRITERIA: 
                 Patients with components of Metabolic syndrome were included in the 
study.             
EXCLUSION CRITERIA: 
 History of Myocardial infarction  
 Coronary bypass surgery 
 Chronic hepatic disease 
 Chronic renal disease 
 Cancer  
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 Alcohol abuse  
 Pregnant females. 
                  The participants of the study were routinely measured for height and 
weight. BMI was calculated with the formula weight/height2 (kg/m2). All the 
participants were informed about the study and informed consents were obtained 
from them. Waist circumference was measured for each subject. 
SAMPLE COLLECTION:  
                 Venous blood samples were drawn from each subject, under aseptic 
precautions, after an overnight fast of 12 hours. The samples were allowed to clot 
for 30 minutes and were centrifuged at 3000g for 10 minutes. The sera for 
estimating FGF 19 were stored in the deep freezer, until the estimation was done. 
The following parameters were estimated immediately after the serum separation. 
1. Blood Glucose – fasting and postprandial. 
2. Fasting lipid profile:  
- Total cholesterol 
- HDL cholesterol 
- Triacylglycerol. 
                   LDL and VLDL cholesterol levels were calculated from the estimated 
parameters using Friedewald formula. AIP (Atherogenic Index of Plasma) was 
calculated as log (TG/HDL-C). Fasting serum FGF 19 was measured in all the 
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samples within one month of collecting the samples by Sandwich Enzyme – 
Linked Immuno Sorbent Assay.  
ESTIMATION OF SERUM FGF 19: 
Reagents provided in the kit purchased: 
i. Item A – Human FGF 19 micro plate – consists of 96 wells coated with 
anti-human FGF 19(12 strips x 8 wells). 
ii. Item B – 25ml of 20x concentrated wash buffer solution. 
iii. Item C – Standards – Recombinant human FGF 19(2 vials) 
iv. Item L – Assay diluent C - Diluent buffer – for standard/sample 
(serum/plasma) - (30ml) 
v. Item E - Assay diluent B – Diluent buffer of 5x concentration - for 
standard/sample (cell culture medium/urine) - (15ml) 
vi. Item F – Detection antibody – Biotinylated anti-human FGF 19 (2 vials) 
vii. Item G – HRP conjugated Streptavidin concentrate – 500x (200 µl) 
viii. Item H – TMB (γ,γ’,5,5’ – Tetra Methyl Benzidine) substrate reagent in 
buffer solution – (12ml) 
ix. Item I - Stop solution – 0.2 M sulphuric acid (8ml). 
Procedure: 
                The assay kit is an in vitro Enzyme – Linked Immuno Sorbent Assay for 
estimating FGF 19. An antibody specific for FGF 19 is coated on a 96-well plate. 
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Standards and samples are pipetted into the appropriate wells. FGF 19 present in 
the sample is bound with the antibodies coated on the wells. After washing the 
wells, a Biotinylated anti-human FGF 19 antibody is added. Again the wells are 
washed to remove unbound Biotinylated antibody. HRP-conjugated Streptavidin is 
added to the wells. Washing is repeated. A TMB substrate solution is added and 
the colour develops in proportion to the concentration of FGF 19 bound in each 
well. After adding Stop solution, the colour changes from blue to yellow. The 
intensity of the colour is measured with an ELISA reader at 450nm. 
Preparation of Reagents: 
i. All the reagents and samples were brought to room temperature before 
usage. 
ii. STANDARD PREPARATION:  
- 400 µl of Assay diluent C was added to the vials 
containing the standard (Item C), after spinning the 
vial briefly. The concentration of this preparation was 
50 ng/ml. 
- By a gentle mix, the powder was dissolved 
thoroughly. 
- 80 µl of the prepared standard in vial (50 ng/ml) was 
added to the 420 µl of Assay diluent C in to a tube to 
prepare 8000 pg/ml standard solution. 
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- 300 µl of Assay diluent C was pipetted into each tube. 
- A dilution series was produced from the 8000 pg/ml 
standard solution as follows.  
- Each tube was mixed thoroughly mixed before 
transferring its contents to the next tube. 
- The Assay diluent C serves as the zero standard (0 
pg/ml) 
80 µl std 
+420 µl   200 µl     200 µl          200 µl          200 µl         200 µl         200 µl 
 
 
 
 
      
     S1               S2              S3                S4              S5              S6               S7               S8 
   8000           3200          1280              512          204.8          81.92          32.77             0       
   pg/ml         pg/ml          pg/ml         pg/ml         pg/ml           pg/ml         pg/ml        pg/ml 
 
iii. WASH BUFFER: 20 ml of wash buffer concentrate (20x) from Item B 
was diluted with distilled or deionised water to yield 400ml of 1x wash 
buffer. 
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iv. DETECTION ANTIBODY: After briefly spinning the vial (Item F), 
100 µl of 1x Assay diluent B was added in to it. Then, the vial was 
mixed gently by pipetting up and down. This detection antibody 
concentrate was diluted with 8 ml of 1x Assay diluent B to make the 
dilution 80 fold. 
v. HRP STREPTAVIDIN: HRP Streptavidin concentrate vial was 
pipetted up and down to mix thoroughly before use, after briefly 
spinning the vial. 20 µl of the concentrate was diluted with 10 ml 1x 
Assay diluent B to prepare a 500 fold diluted solution. 
STEPS: 
i. All reagents and standards were prepared as instructed and allowed to 
attain room temperature before use. 
ii. 100 µl of the standard and sample was added to each well. 
iii. The wells incubated for 2.5 hours at room temperature. 
iv. After the incubation period, 100 µl of the prepared Streptavidin solution 
was added to each well.  
v. Allowed incubation at room temperature for 45 minutes. 
vi. 100 µl of TMB substrate reagent was added to each well. And again 
incubated for 30 minutes at room temperature. 
vii. 50 µl of Stop solution was added to each well. 
viii. Readings were taken at 450 nm immediately.  
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Calculation of results: 
                      A Standard curve was plotted with the standard concentration on the 
x-axis and the absorbance on the y-axis. The best fit straight line was drawn 
through the points on the graph. Using the absorbance value for each sample, the 
corresponding concentration of FGF 19 was calculated from the standard curve. 
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ESTIMATION OF GLUCOSE: 
Method:  
                Glucose Oxidase – Peroxidase method (End point) 
Principle:  
              Glucose present in the sample is oxidized to Gluconic acid and hydrogen 
peroxide by Glucose oxidase (GOD). Peroxidase enzyme (POD) acts on hydrogen 
peroxide to yield water and nascent oxygen. This nascent oxygen oxidizes phenol, 
which in turn combines with 4-aminoantipyrine to form a coloured quinoneimine 
complex. The intensity of the colour is directly proportional to the concentration 
of Glucose in the sample. 
  Glucose + O2 + H2O                   GOD                Gluconic acid + H2O2 
    H2O2 + Phenol + 4AAP                POD            Quinoneimine dye + 2H2O 
Glucose standard: 100 mg/dl 
Enzyme Reagent Composition:  
                   Glucose oxidase    : ≥ β0000 U/L 
                   Peroxidase             : ≥ β000 U/L  
                   Phenol                    : 10 mmol/L 
                   Phosphate buffer   : 200 mmol/L. 
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Specimen: Fresh unhemolysed serum. 
Assay Parameters:  
Wavelength-1                   : 505 nm 
Wavelength-2                   : 670 nm 
Reaction time                   : 5 minutes 
Reaction temperature       : 37ºC 
Reagent volume               : 1000 µl 
Sample volume                 : 10 µl 
Blank Absorbance Limit   : 0.2 
Units                                 : mg/dl 
Assay procedure: (End point method) 
Pipette into test tubes 
labelled as 
Blank Standard Test 
Enzyme reagent 1ml 1ml 1ml 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
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                     The tubes were mixed well after each addition and incubated at 37ºC 
for 5 minutes. The absorbance of standard and test was read at 505 nm. 
Calculation:     
                                         Absorbance of Test 
Glucose (mg/dl) =                                                         x   concentration of Standard 
                                     Absorbance of Standard                 
                 
Linearity: Up to 500 mg/dl. 
Normal values:  Glucose (fasting): 70 – 110 mg/dl 
                            Glucose (post prandial): 90 – 140 mg/dl 
ESTIMATION OF SERUM TOTAL CHOLESTEROL: 
Method:  
                    Cholesterol oxidase-Peroxidase Enzymatic, endpoint method. 
Principle:  
                   The free cholesterol, liberated from the cholesterol esters by 
cholesterol esterase (CHE), is oxidized by cholesterol oxidase (CHO) to 
cholestenone with the simultaneous production of hydrogen peroxide. The  
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hydrogen peroxide reacts with 4-aminoantipyrine (4AAP) and a phenolic 
compound in the presence of peroxidase (POD) to yield a red coloured complex.  
  Cholesterol ester + Water                 CHE          Cholesterol + Fatty acid
 
  Cholesterol + Oxygen                       CHO                Cholest-4-en-3-one + H2O2       
  2
 
H2O2 + 4AAP+ Phenol                  POD                Quinoneimine dye + 4H2O  
       Absorbance of quinoneimine formed is directly proportional to 
cholesterol concentration.            
Reagent Composition:    
               Goods buffer (pH – 6.4)     : 100 mmol/L 
               Cholesterol oxidase            : >100 U/L 
               Cholesterol esterase            : >200 U/L 
               Peroxidase                           : >3000 U/L 
               4 – Amino antipyrine          : 0.3 mmol/L 
               Phenol                                 : 5 mmol/L 
Cholesterol standard: 200mg/dl 
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Assay Parameters:  
Wavelength-1                   : 505 nm 
Wavelength-2                   : 670 nm 
Incubation time                 : 10 minutes 
Incubation temperature     : 37ºC 
Reagent volume                : 1000 µl 
Sample volume                 : 10 µl 
Absorbance Limit             : 0.4 
Blank with                        : Reagent 
Units                                 : mg/dl 
Assay procedure: (End Point Method) 
Pipette into test 
tubes labelled as Blank Standard Test 
Working reagent 1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
 
90 
 
                        Mixed well and incubated for 10 min at room temperature. The 
absorbance of the test and standard were read against reagent blank at 505 nm. 
Calculation: 
                                                Absorbance of test 
Cholesterol (mg/dl) =                                                   X   concentration of standard  
                                            Absorbance of standard 
 
Reference range: 150-200 mg/dl      
Linearity: Up to 1000 mg/dl 
Sensitivity: 1mg/dl 
Interference: Hemoglobin upto 200mg/dl, Ascorbate upto 12mg/dl, Bilirubin 
upto 10mg/dl and Triglycerides upto 700 mg/dl do not interfere with the test. 
ESTIMATION OF SERUM TRIGLYCERIDES: 
Method: GPO-PAP method, Endpoint. 
Methodology: Colorimetric, Enzymatic method with Glycerol Phosphate Oxidase 
(GPO). 
Principle: Lipoprotein lipase (LPL) catalyzed hydrolysis of Triacylglycerol, 
yields Glycerol which is phosphorylated by Glycerol kinase (GK) using ATP to 
Glycerol-3-phosphate, which upon oxidation by the enzyme Glycerol Phosphate 
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Oxidase (GPO), yields Di-Hydroxy Acetone Phosphate and Hydrogen peroxide. 
The Hydrogen peroxide reacts with Phenolic compound and 4-Amino Anti Pyrine 
in the presence of Peroxidase (POD) to form a coloured complex. The intensity of 
Quinoneimine dye formed is proportional to the Triglyceride concentration in the 
sample. 
Triglycerides + H2O                          LPL                 Glycerol + free fatty acids 
Glycerol + ATP                                   GK                   Glycerol 3 phosphate + ADP 
Glycerol 3 phosphate + O2               GPO                 DHAP + H2O2 
H2O2 + 4AAP+ 3,5-DHBS              POD                 Quinoneimine dye + 2H2O 
     [DHAP -Di-Hydroxy Acetone Phosphate 
      ATP    - Adenosine Tri Phosphate 
      4-AAP - 4 Amino Anti Pyrine 
      DHBS   -3,5 Dichloro-2 Hydroxy Benzene Sulfonate] 
Triglycerides standard concentration- 200mg/dl 
Reagent composition: 
                 Buffer (pH – 7.0)   : 40 mmol/L 
                 4-AAP                   : 0.4 mmol/L 
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                 ATP                       : 2.0 mmol/L 
                 Mg2+                                  : 2.5 mmol/L 
                         DHBS                    : 0.2 mmol/L 
                   
    Glycerol kinase     : 1500 U/L 
                 Glycerol 3 – phosphate oxidase   : 4000 U/L 
                         
 Peroxidase         : 2200 U/L 
                 Lipoprotein lipase   : 4000 U/L 
Reagent Preparation: 
   Reagent 1 (R1) - Enzymes / chromogen 
   Reagent 2 (R2) - Buffer 
      The working reagent was prepared by mixing 4 parts of R1 with 1 part of 
R2.  
Sample: Unhemolysed serum collected after 12 hrs of fasting. 
Assay Parameters:  
Wavelength-1                   : 505 nm 
Wavelength-2                   : 670 nm 
Incubation time                 : 10 minutes 
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Incubation temperature     : 37ºC 
Reagent volume                : 1000 µl 
Sample volume                 : 10 µl 
Absorbance Limit             : 0.5 
Blank with                        : Reagent 
Units                                 : mg/dl 
Assay Procedure: 
Pipette into test 
tubes labelled as Blank Standard Test 
Working reagent 1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
 
           Mixed and incubated for 10min, at room temperature. Absorbance 
was read at 505nm for standard and sample against reagent blank. 
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Calculation: 
                                               Absorbance of test 
Triglycerides (mg/dl) =                                               X   Concentration of standard  
                                             Absorbance of standard 
 
Reference values: 50 -150 mg/dl 
Linearity: Upto 1000mg/dl 
Sensitivity: 2mg/dl 
Interferences:  Hemoglobin upto 300mg/dl, Ascorbate upto 3mg/dl and Bilirubin 
upto 20mg/dl do not interfere with the test. 
 
ESTIMATION OF SERUM HDL - CHOLESTEROL: 
METHOD: Phosphotungstic acid method, Endpoint. 
PRINCIPLE: Chylomicrons (CM), LDL and VLDL are precipitated from serum 
or plasma with Phosphotungstate in the presence of divalent cations such as 
Magnesium. The HDL cholesterol remains unaffected in the supernatant and is 
estimated using cholesterol reagent.    
                     
95 
 
Serum/plasma                                                       HDL      +     [LDL+VLDL+CM] 
                               (supernatant)                 (precipitate) 
 
REAGENT COMPOSITION: 
Precipitating reagent:  
Phosphotungstic acid 0.4 mmol/L 
Magnesium chloride 20 mmol/L 
 
HDL cholesterol standard – 15mg/dl 
Sample: Unhemolysed serum 
PRECIPITATION: 
Precipitation of LDL, VLDL and Chylomicrons done as follows: 
 
 
 
            Mixed well and the reaction mixture was allowed to stand for 10 
min at room temperature, centrifuged at 4000 rpm for 10min and collected the 
Pipette into tubes Volume 
Sample 200µl 
Precipitating reagent 500µl 
         Phosphotungstic acid, Mg2+ 
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clear supernatant. The supernatant was used to determine the concentration of 
HDL cholesterol in the sample. 
Assay procedure: 
 
   Mixed well and incubated for 10 minutes at room temperature. 
The absorbance of the standard and the test samples were read at 500 nm against 
reagent blank. 
Calculation: 
                                           Absorbance of test 
HDL Cholesterol   =                                               X Conc. of std. X Dilution factor  
      (mg/dl)                      Absorbance of standard 
                                             Absorbance of test 
                              =                                                          X   52.5 
                                           Absorbance of standard 
                              =         mg/dl HDL Cholesterol. 
 
 
Pipette into tubes marked Blank Standard Test 
Cholesterol working reagent 1000µl 1000µl 1000µl 
Distilled water 100µl - - 
HDL Cholesterol standard - 100µl - 
Sample Supernatant - - 100µl 
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Reference values: 35 – 60 mg/dl        
Linearity: 150 mg/dl; Detection limit: 3.0 mg/dl 
 
ESTIMATION OF SERUM LDL CHOLESTEROL: 
BY FRIEDEWALD FORMULA: 
LDL = TOTAL CHOLESTEROL – (HDL + VLDL) 
VLDL = TGL/5, if TGL is less than 400mg/dl. 
Reference values: 
                Serum / plasma LDL: 100 – 129 mg/dl 
                VLDL:  < 40 mg/dl. 
 
 
CALCULATION OF ATHEROGENIC INDEX OF PLASMA (AIP) 
AIP = log (TGL / HDL) 
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MASTER CHART – I 
CONTROL GROUP 
S.No. AGE SEX SBP (mmHg) 
DBP 
(mmHg) 
WC 
(cm) 
WT 
(Kg) 
HT 
(m) BMI 
LIPID PROFILE 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
 
AIP 
FGF 
19 
(pg/ml) TC TGL HDL LDL VLDL 
1 43 F 126 82 83 55 1.52 23.81 154 122 45 84.6 24.4 83 126 0.43315 313 
2 49 F 130 80 80 61 1.60 23.83 160 134 48 85.2 26.8 93 133 0.44586 217 
3 31 F 126 80 92 53 1.52 22.94 146 128 52 68.4 25.6 72 138 0.39121 327 
4 29 F 114 70 84 55 1.58 22.03 158 114 53 82.2 22.8 83 125 0.33263 181 
5 26 F 130 82 88 62 1.56 25.48 142 106 41 79.8 21.2 80 130 0.41252 176 
6 24 F 120 80 90 52 1.54 21.93 166 104 45 100.2 20.8 77 138 0.36382 283 
7 32 F 110 70 85 60 1.58 24.03 172 118 47 101.4 23.6 95 121 0.39978 367 
8 53 F 130 80 79 53 1.60 20.70 146 98 48 78.4 19.6 86 129 0.30998 296 
9 49 F 114 80 87 47 1.55 19.56 150 102 52 77.6 20.4 91 115 0.2926 224 
10 46 F 126 76 85 51 1.53 21.79 160 96 45 95.8 19.2 79 120 0.32906 322 
11 45 F 120 80 86 64 1.60 25.0 176 124 42 109.2 24.8 74 118 0.47017 226 
12 38 F 112 80 82 48 1.53 20.50 162 118 50 88.4 23.6 85 114 0.37291 259 
13 43 F 124 84 85 54 1.59 21.36 158 104 44 93.2 20.8 90 120 0.37358 232 
14 28 F 116 70 90 58 1.62 22.10 172 112 48 101.6 22.4 89 131 0.36798 294 
15 42 F 128 82 95 58 1.59 22.94 168 96 41 107.8 19.2 96 119 0.36949 185 
16 52 F 112 70 93 52 1.54 21.93 154 82 45 92.6 16.4 93 123 0.2606 180 
17 42 F 100 80 91 51 1.50 22.67 150 94 48 83.2 18.8 82 130 0.29189 320 
18 39 F 126 76 89 45 1.42 22.32 146 78 40 90.4 15.6 77 132 0.29003 346 
19 48 F 124 80 84 54 1.60 21.09 168 118 52 92.4 23.6 90 128 0.35588 201 
20 39 F 116 72 84 54 1.52 23.37 158 110 44 92 22 74 122 0.39794 192 
21 52 F 104 76 87 53 1.52 22.94 142 128 40 76.4 25.6 83 119 0.50515 207 
22 31 F 114 78 88 54 1.59 21.36 164 132 48 89.6 26.4 89 132 0.43933 323 
23 38 F 124 80 91 53 1.51 23.24 172 120 51 97 24 95 137 0.37161 324 
24 29 F 128 78 93 60 1.58 24.03 166 114 42 101.2 22.8 91 122 0.43366 294 
25 49 F 120 70 85 54 1.51 23.68 168 122 47 96.6 24.4 95 111 0.41426 167 
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26 37 M 128 80 83 56 1.60 21.88 154 102 48 85.6 20.4 84 135 0.32736 168 
27 42 M 136 82 88 55 1.57 22.31 146 96 52 74.8 19.2 90 128 0.26627 334 
28 48 M 130 80 83 62 1.60 24.22 132 76 41 75.8 15.2 73 131 0.26803 360 
29 30 M 128 74 94 54 1.62 20.58 146 82 45 84.6 16.4 85 138 0.2606 244 
30 41 M 126 80 92 52 1.56 21.37 178 108 48 108.4 21.6 83 129 0.35218 231 
31 60 M 130 82 82 60 1.62 22.86 166 114 44 99.2 22.8 94 125 0.41345 347 
32 32 M 120 74 98 64 1.60 25 141 84 47 77.2 16.8 90 130 0.25218 355 
33 52 M 126 76 83 62 1.58 24.84 154 118 54 76.4 23.6 86 112 0.33949 315 
34 33 M 130 80 91 56 1.59 22.15 134 80 42 76 16 76 113 0.27984 373 
35 40 M 124 82 88 54 1.56 22.19 146 92   45 82.6 18.4 92 136 0.31058 306 
36 46 M 128 76 90 46 1.54 19.39 178 96 48 110.8 19.2 78 125 0.30103 297 
37 38 M 110 70 87 50 1.64 18.59 159 120 46 89 24 88 132 0.41642 273 
38 49 M 120 78 79 56 1.53 23.92 165 111 41 101.8 22.2 72 145 0.43254 229 
39 33 M 124 80 82 60 1.62 22.86 149 99 50 79.2 19.8 92 139 0.29667 175 
40 50 M 130 84 87 52 1.56 21.37 144 109 44 78.2 21.8 75 122 0.39397 171 
41 45 M 126 76 80 56 1.63 21.08 178 92 45 114.6 18.4 88 139 0.31058 267 
42 41 M 122 80 92 60 1.57 24.34 168 124 41 102.2 24.8 94 136 0.48064 173 
43 55 M 120 70 94 62 1.65 22.77 152 118 52 76.4 23.6 74 127 0.35588 285 
44 22 M 120 84 82 58 1.63 21.83 167 95 49 99 19 92 133 0.28753 287 
45 42 M 110 70 85 58 1.60 22.66 146 102 44 81.6 20.4 78 115 0.36515 296 
46 26 M 124 78 79 62 1.70 21.45 170 110 45 103 22 87 121 0.38818 231 
47 53 M 120 78 94 60 1.71 20.52 154 114 41 90.2 22.8 94 127 0.44412 364 
48 39 M 114 70 83 54 1.63 20.32 163 98 44 99.4 19.6 95 118 0.34777 179 
49 52 M 130 82 80 60 1.68 21.26 180 126 54 100.8 25.2 83 137 0.36798 362 
50 26 M 126 80 79 64 1.75 20.89 146 104 48 77.2 20.8 90 120 0.33579 239 
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MASTER CHART – II 
STUDY GROUP 
S.No. AGE SEX SBP (mmHg) 
DBP 
(mmHg) 
WC 
(cm) 
WT 
(Kg) 
HT 
(m) BMI 
LIPID PROFILE 
FBS 
(mg/dl) 
PPBS 
(mg/dl) 
 
AIP 
FGF 
19 
(pg/ml) TC TGL HDL LDL VLDL 
1 46 F 140 96 104 90 1.51 39.47 260 272 32 173.6 54.4 125 186 0.92942 110 
2 52 F 130 88 95 81 1.55 33.71 232 240 36 148 48 118 172 0.82391 125 
3 43 F 132 90 96 84 1.53 35.88 238 252 31 156.6 50.4 118 167 0.91004 130 
4 54 F 138 94 102 92 1.60 35.94 256 268 34 168.4 53.6 122 182 0.89666 116 
5 48 F 140 92 100 90 1.53 38.45 252 250 36 166 50 123 182 0.84164 114 
6 41 F 130 86 92 77 1.50 34.22 212 186 40 134.8 37.2 112 152 0.66745 142 
7 43 F 132 90 98 91 1.60 35.55 236 248 34 152.4 49.6 124 176 0.86297 122 
8 46 F 136 92 98 84 1.53 35.88 243 252 36 156.6 50.4 120 180 0.8451 120 
9 64 F 142 94 102 87 1.56 35.75 264 292 30 175.6 58.4 124 188 0.98826 104 
10 42 F 132 86 87 82 1.62 31.25 206 164 41 132.2 32.8 114 164 0.60206 157 
11 53 F 134 90 96 99 1.60 38.67 236 248 37 149.4 49.6 118 176 0.82625 124 
12 49 F 132 88 90 77 1.55 32.05 212 172 40 137.6 34.4 118 167 0.63347 153 
13 47 F 130 84 86 73 1.56 29.99 210 166 40 136.8 33.2 111 143 0.61805 171 
14 51 F 132 88 94 86 1.58 34.45 232 244 38 145.2 48.8 116 174 0.80761 126 
15 45 F 134 90 94 91 1.60 35.55 240 234 38 155.2 46.8 114 163 0.78943 138 
16 52 F 130 84 90 81 1.55 33.71 213 204 40 132.2 40.8 106 152 0.70757 145 
17 49 F 138 90 102 90 1.55 37.46 242 248 37 155.4 49.6 121 181 0.82625 118 
18 62 F 130 88 92 81 1.55 33.71 230 240 39 143 48 115 170 0.78915 130 
19 58 F 134 90 96 91 1.60 35.55 256 244 36 171.2 48.8 118 172 0.83109 128 
20 71 F 132 88 100 81 1.55 33.71 247 236 37 162.8 47.2 118 180 0.80471 119 
21 54 F 132 86 90 77 1.55 32.05 228 234 41 140.2 46.8 116 162 0.75643 132 
22 63 F 135 92 98 91 1.58 36.45 214 261 36 125.8 52.2 119 175 0.86034 123 
23 49 F 134 92 96 84 1.53 35.88 240 270 30 156 54 120 172 0.95424 129 
24 53 F 130 86 88 86 1.65 31.59 210 168 42 134.4 33.6 116 165 0.60206 160 
25 46 F 134 86 94 84 1.61 32.41 224 196 41 143.8 39.2 109 150 0.67947 144 
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26 45 M 142 94 102 93 1.52 40.25 265 284 31 177.2 56.8 124 187 0.96196 103 
27 38 M 132 90 95 83 1.54 34.99 232 256 32 148.8 51.2 118 165 0.90309 134 
28 43 M 144 94 106 94 1.52 40.69 273 285 29 187 57 123 191 0.99245 102 
29 42 M 130 86 93 84 1.56 34.52 216 234 35 134.2 46.8 114 153 0.82515 148 
30 42 M 132 85 94 82 1.62 31.25 219 195 42 138 39 111 148 0.66679 153 
31 52 M 136 90 100 88 1.54 37.11 240 234 39 154.2 46.8 118 176 0.77815 127 
32 44 M 138 94 98 85 1.52 36.79 226 265 34 139 53 123 182 0.89177 113 
33 39 M 146 94 107 94 1.51 41.23 276 281 29 190.8 56.2 125 194 0.98631 100 
34 48 M 130 82 86 72 1.53 30.76 205 163 43 129.4 32.6 110 146 0.57872 167 
35 46 M 132 80 88 75 1.6 29.29 209 159 44 133.2 31.8 112 145 0.55794 172 
36 52 M 130 82 88 87 1.62 33.15 226 232 39 140.6 46.4 116 164 0.77442 145 
37 39 M 134 88 96 81 1.52 35.06 235 224 35 155.2 44.8 123 167 0.80618 141 
38 38 M 136 94 97 88 1.57 35.70 264 259 34 178.2 51.8 126 182 0.88182 118 
39 52 M 128 88 96 81 1.54 34.15 208 228 37 125.4 45.6 109 143 0.78973 158 
40 49 M 134 86 98 82 1.61 31.63 226 199 39 147.2 39.8 120 158 0.70779 133 
41 37 M 132 86 92 81 1.56 33.28 231 243 35 147.4 48.6 124 172 0.84154 124 
42 42 M 136 94 106 87 1.52 37.66 246 239 36 162.2 47.8 125 186 0.8221 117 
43 48 M 135 86 98 88 1.58 35.25 239 231 36 156.8 46.2 122 165 0.80731 144 
44 37 M 130 82 88 74 1.57 30.02 217 178 40 141.4 35.6 115 158 0.64836 163 
45 41 M 128 86 92 73 1.56 29.99 223 184 38 148.2 36.8 119 171 0.68503 161 
46 60 M 130 80 91 70 1.55 29.14 224 178 39 149.4 35.6 111 156 0.65936 171 
47 46 M 132 85 95 87 1.63 32.74 228 234 38 143.2 46.8 121 162 0.78943 144 
48 52 M 128 86 87 70 1.57 28.39 220 198 42 138.4 39.6 113 161 0.67342 175 
49 63 M 142 90 108 99 1.65 36.36 276 308 32 182.4 61.6 126 187 0.9834 102 
50 40 M 132 87 88 77 1.61 29.71 235 228 38 151.4 45.6 119 173 0.77815 156 
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STATISTICAL ANALYSIS 
 
 Student’s t-test was employed for the statistical analysis of data.  
 The data were expressed in terms of mean and standard deviation. 
 ‘p’ value less than 0.05 was taken as the significant value. 
 Correlation between the measured parameters was assessed using Pearson’s 
correlation coefficient. 
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STATISTICS 
TABLE 1 
DESCRIPTIVE STATISTICS OF CONTROL AND CASES 
 
Variables 
Control (n=50) Cases (n=50) 
Min Max Mean S.D. Min Max Mean S.D. 
SBP 100.0 136.0 121.920 7.6127 128.0 146.0 133.840 4.3064 
DBP 70.0 84.0 77.640 4.4020 80.0 96.0 88.380 3.9790 
WC 79.0 98.0 86.620 4.9193 86.0 108.0 95.380 5.7743 
WT 45.0 64.0 55.880 4.7623 70.0 99.0 84.100 7.0313 
HT 1.42 1.75 1.5828 0.05838 1.50 1.65 1.5652 0.0384 
BMI 18.59 25.47 22.305 1.5341 28.39 41.22 34.369 3.1321 
TC 132.0 180.0 157.880 12.1834 205.0 276.0 233.840 19.1326 
TGL 76.0 134.0 106.880 14.7864 159.0 308.0 230.160 37.8015 
HDL 40.0 54.0 46.320 3.9354 29.0 44.0 36.760 3.7881 
VLDL 15.2 26.8 21.376 2.9573 31.8 61.6 46.032 7.5603 
LDL 68.4 114.6 90.184 11.5157 125.4 190.8 151.048 16.1828 
FBS 72.0 96.0 85.500 7.3158 106.0 126.0 118.040 5.1109 
PPBS 111.0 145.0 126.920 8.2853 143.0 194.0 168.860 13.4271 
AIP .2521 0.5051 0.3603 0.06328 0.55794 0.99244 0.79287 0.11597 
FGF 19 167.0 373.0 266.340 65.5070 100.0 175.0 135.020 20.7556 
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TABLE 2: STATISTICAL ANALYSIS OF SERUM FGF 19 
BETWEEN CASES AND CONTROLS 
T-TEST 
FGF 19 
(pg/ml) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 266.340 65.5070  
p value = .000 
<0.05 – Significant Cases (n=50) 135.020 20.7556 
 
BAR CHART 1 
COMPARISON OF SERUM FGF 19 LEVEL 
BETWEEN CONTROLS AND CASES 
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TABLE 3: STATISTICAL ANALYSIS OF AIP 
BETWEEN CASES AND CONTROLS 
T-TEST 
AIP 
 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 0.3603 0.06328  
p value = .000 
<0.05 – Significant Cases (n=50) 0.79287 0.11597 
 
BAR CHART 2 
COMPARISON OF SERUM AIP 
BETWEEN CONTROLS AND CASES 
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TABLE 4: STATISTICAL ANALYSIS OF FBS 
BETWEEN CASES AND CONTROLS 
T-TEST 
FBS 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 85.500 7.3158  
p value = .000 
<0.05 – Significant Cases (n=50) 118.040 5.1109 
 
BAR CHART 3 
COMPARISON OF SERUM FBS 
BETWEEN CONTROLS AND CASES 
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TABLE 5: STATISTICAL ANALYSIS OF PPBS 
BETWEEN CASES AND CONTROLS 
T-TEST 
PPBS 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 126.920 8.2853  
p value = .000 
<0.05 – Significant Cases (n=50) 168.860 13.4271 
 
BAR CHART 4 
COMPARISON OF SERUM PPBS 
BETWEEN CONTROLS AND CASES 
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TABLE 6: STATISTICAL ANALYSIS OF TC 
BETWEEN CASES AND CONTROLS 
T-TEST 
TC 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 157.880 12.1834  
p value = .000 
<0.05 – Significant Cases (n=50) 233.840 19.1326 
 
BAR CHART 5 
COMPARISON OF SERUM TC 
BETWEEN CONTROLS AND CASES 
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TABLE 7: STATISTICAL ANALYSIS OF TGL 
BETWEEN CASES AND CONTROLS 
T-TEST 
TGL 
(mg/dl) 
 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 
106.880 14.7864 
 
p value = .000 
<0.05 – Significant Cases (n=50) 230.160 37.8015 
 
BAR CHART 6 
COMPARISON OF SERUM TGL 
BETWEEN CONTROLS AND CASES 
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TABLE 8: STATISTICAL ANALYSIS OF HDL 
BETWEEN CASES AND CONTROLS 
T-TEST 
HDL 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 46.320 3.9354  
p value = .000 
<0.05 – Significant Cases (n=50) 36.760 3.7881 
 
BAR CHART 7 
COMPARISON OF SERUM HDL 
BETWEEN CONTROLS AND CASES 
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TABLE 9: STATISTICAL ANALYSIS OF VLDL 
BETWEEN CASES AND CONTROLS 
T-TEST 
VLDL 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 21.376 2.9573  
p value = .000 
<0.05 – Significant Cases (n=50) 46.032 7.5603 
 
BAR CHART 8 
COMPARISON OF SERUM VLDL 
BETWEEN CONTROLS AND CASES 
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TABLE 10: STATISTICAL ANALYSIS OF LDL 
BETWEEN CASES AND CONTROLS 
T-TEST 
LDL 
(mg/dl) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 90.184 11.5157  
p value = .000 
<0.05 – Significant Cases (n=50) 151.048 16.1828 
 
BAR CHART 9 
COMPARISON OF SERUM LDL 
BETWEEN CONTROLS AND CASES
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TABLE 11: STATISTICAL ANALYSIS OF HEIGHT 
BETWEEN CASES AND CONTROLS 
T-TEST 
HEIGHT 
(mt) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 1.5828 0.05838  
p value = .042 
<0.05 – Significant Cases (n=50) 1.5652 0.0384 
 
BAR CHART 10 
COMPARISON OF HEIGHT 
BETWEEN CONTROLS AND CASES 
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TABLE 12: STATISTICAL ANALYSIS OF WEIGHT 
BETWEEN CASES AND CONTROLS 
T-TEST 
WEIGHT 
(kg) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 55.880 4.7623  
p value = .000 
<0.05 – Significant Cases (n=50) 84.100 7.0313 
 
BAR CHART 11 
COMPARISON OF WEIGHT 
BETWEEN CONTROLS AND CASES 
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TABLE 13: STATISTICAL ANALYSIS OF BMI 
BETWEEN CASES AND CONTROLS 
T-TEST 
BMI 
(kg/m2) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 22.305 1.5341  
p value = .000 
<0.05 – Significant Cases (n=50) 34.369 3.1321 
 
BAR CHART 12 
COMPARISON OF BMI 
BETWEEN CONTROLS AND CASES
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TABLE 14: STATISTICAL ANALYSIS OF WAIST CIRCUMFERENCE 
BETWEEN CASES AND CONTROLS 
T-TEST 
WC 
(cm) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 86.620 4.9193  
p value = .000 
<0.05 – Significant Cases (n=50) 95.380 5.7743 
 
BAR CHART 13 
COMPARISON OF WAIST CIRCUMFERENCE 
BETWEEN CONTROLS AND CASES 
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TABLE 15: STATISTICAL ANALYSIS OF SYSTOLIC BP 
BETWEEN CASES AND CONTROLS 
T-TEST 
SYSTOLIC BP 
(mmHg) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 121.920 7.6127  
p value = .000 
<0.05 – Significant Cases (n=50) 133.840 4.3064 
 
BAR CHART 14 
COMPARISON OF SYSTOLIC BP 
BETWEEN CONTROLS AND CASES 
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TABLE 16: STATISTICAL ANALYSIS OF DIASTOLIC BP 
BETWEEN CASES AND CONTROLS 
T-TEST 
DIASTOLIC BP 
(mmHg) 
MEAN SD STATISTICAL 
INFERENCE 
Control (n=50) 77.640 4.4020  
p value = .000 
<0.05 – Significant Cases (n=50) 88.380 3.9790 
 
BAR CHART 15 
COMPARISON OF DIASTOLIC BP 
BETWEEN CONTROLS AND CASES 
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TABLE 17: 
PEARSONS CORRELATION BETWEEN FGF 19 
AND OTHER PARAMETERS 
CASES – FGF 19 
CORRELATION 
VALUE 
STATISTICAL 
INFERENCE 
BMI -0.875 P < 0.01 Significant 
WAIST 
CIRCUMFERENCE 
-0.864 P < 0.01 Significant 
SBP -0.808 P < 0.01 Significant 
DBP -0.841 P < 0.01 Significant 
FBS -0.754 P < 0.01 Significant 
PPBS -0.853 P < 0.01 Significant 
TC -0.827 P < 0.01 Significant 
TGL -0.892 P < 0.01 Significant 
HDL +0.773 P < 0.01 Significant 
VLDL -0.892 P < 0.01 Significant 
LDL -0.742 P < 0.01 Significant 
AIP -0.873 P < 0.01 Significant 
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RESULTS 
                    A total of 100 participants were included in the study. Out of these, 50 
were grouped under controls and 50 were under cases.  
                   The serum value of FGF 19, fasting and post prandial blood sugar, 
Total Cholesterol, HDL and TGL were estimated for all the samples in both the 
groups. BMI, VLDL, LDL and AIP were calculated. The values obtained for the 
cases and controls are represented in the master chart I and II respectively. 
TABLE: 1 
                   Shows the descriptive base line statistics of the controls and the cases. 
It includes the mean values of Anthropometric data, Blood pressure, serum FGF 
19, AIP, Fasting and Post prandial blood sugars and Lipid profile. 
TABLE: 2 
                   Shows student’s t-test analysis of serum FGF 19 level between cases 
and controls. 
                   There is decrease in the mean serum FGF 19 in cases (135.02 ± 20.76 
pg/ml), when compared to the mean serum FGF 19 in controls (266.34 ± 65.5 
pg/ml), which is statistically significant. (p value < 0.05). 
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TABLE: 3 
               Shows student’s t-test analysis of serum AIP between cases and controls. 
                   There is increase in the mean AIP in cases (0.79± 0.12), when 
compared to the mean AIP in controls (0.36± 0.06), which is statistically 
significant. (p value < 0.05).  
TABLE: 4 
                   Shows student’s t-test analysis of serum FBS between cases and 
controls. 
                   There is increase in the mean FBS in cases (118.04 ± 5.11), when 
compared to the mean FBS in controls (85.5 ± 7.32), which is statistically 
significant. (p value < 0.05). 
TABLE: 5 
                   Shows student’s t-test analysis of serum PPBS between cases and 
controls. 
                   There is increase in the mean PPBS in cases (168.86 ± 13.43), when 
compared to the mean PPBS in controls (126.9 ± 8.29), which is statistically 
significant. (p value < 0.05). 
 
 
123 
 
TABLE: 6 
                   Shows student’s t-test analysis of serum TC between cases and 
controls. 
                   There is increase in the mean TC in cases (233.84 ± 19.13), when 
compared to the mean TC in controls (157.88 ± 12.18), which is statistically 
significant. (p value < 0.05). 
TABLE: 7 
                   Shows student’s t-test analysis of serum TGL between cases and 
controls. 
                   There is increase in the mean TGL in cases (230.16 ± 37.8), when 
compared to the mean TGL in controls (106.88 ±14.79), which is statistically 
significant. (p value < 0.05). 
TABLE: 8 
                   Shows student’s t-test analysis of serum HDL between cases and 
controls. 
                   There is decrease in the mean HDL in cases (36.76 ± 3.79), when 
compared to the mean HDL in controls (46.32 ± 3.94), which is statistically 
significant. (p value < 0.05). 
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TABLE: 9 
                   Shows student’s t-test analysis of serum VLDL between cases and 
controls. 
                   There is increase in the mean VLDL in cases (46.03 ±7.56), when 
compared to the mean VLDL in controls (21.38 ± 2.96), which is statistically 
significant. (p value < 0.05). 
TABLE: 10 
                   Shows student’s t-test analysis of serum LDL between cases and 
controls. 
                   There is increase in the mean LDL in cases (151.05 ± 16.18), when 
compared to the mean LDL in controls (90.18 ± 11.52), which is statistically 
significant. (p value < 0.05). 
TABLE: 11 
                   Shows student’s t-test analysis of Height between cases and controls. 
                   There is decrease in the mean Height in cases (1.57 ± 0.04), when 
compared to the mean Height in controls (1.58 ±0.06), which is statistically 
significant. (p value < 0.05). 
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TABLE: 12 
                   Shows student’s t-test analysis of Weight between cases and controls. 
                   There is increase in the mean Weight in cases (84.1 ± 7.03), when 
compared to the mean Weight in controls (55.88 ± 4.76), which is statistically 
significant. (p value < 0.05). 
TABLE: 13 
                   Shows student’s t-test analysis of BMI between cases and controls. 
                   There is increase in the mean BMI in cases (34.37 ± 3.13), when 
compared to the mean BMI in controls (22.31 ± 1.53), which is statistically 
significant. (p value < 0.05). 
TABLE: 14 
                   Shows student’s t-test analysis of Waist circumference between cases 
and controls. 
                   There is increase in the mean Waist circumference in cases (95.38 ± 
5.77), when compared to the mean Waist circumference in controls (86.62 ± 4.92), 
which is statistically significant. (p value < 0.05). 
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TABLE: 15 
                   Shows student’s t-test analysis of Systolic BP between cases and 
controls. 
                   There is increase in the mean Systolic BP in cases (133.84 ± 4.31), 
when compared to the mean Systolic BP in controls (121.92 ± 7.61), which is 
statistically significant. (p value < 0.05). 
TABLE: 16 
                   Shows student’s t-test analysis of Diastolic BP between cases and 
controls. 
                   There is increase in the mean Diastolic BP in cases (88.38 ± 3.98), 
when compared to the mean Diastolic BP in controls (77.64 ± 4.4), which is 
statistically significant. (p value < 0.05). 
TABLE: 17 
                 Pearson correlation between FGF 19 and other parameters. 
                This table shows negative correlation between serum FGF 19 and BMI, 
Waist circumference, systolic and diastolic BP, AIP, fasting and post prandial 
blood sugar, serum TC, TGL, VLDL and LDL concentrations and a positive 
correlation with serum HDL concentration, which are statistically significant. (p < 
0.05) 
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DISCUSSION 
 
                   FGF 19 is a newly identified metabolic regulator, influencing 
homeostasis of glucose and lipid metabolism. It has been concluded that the 
expression of FGF 19 in liver is induced by FXR (Farnesoid X receptor), a 
transcription factor. The natural ligand for the FXR receptor was identified as bile 
acids. So, FXR acts as a “bile acid sensor” inducing the expression of FGF 19.  
FGF 19 inhibits the enzyme CYP7A1 in liver, thereby inhibiting the rate limiting 
step of Bile acid synthesis from Cholesterol. The repression of bile acid synthesis 
is the net result of FXR activation. FXR not only regulates bile acid metabolism, 
but also metabolism of cholesterol, triglyceride, lipoprotein and glucose. The 
dysregulations of glucose, cholesterol and triglyceride metabolism lead to 
Metabolic syndrome.  
                 Animal studies revealed that Recombinant FGF 19 increased the 
metabolic rate, decreased body weight and reversed diabetes. This led to further 
research which suggested that FGF 19 increases oxidation of lipids and increases 
the activity of Carnitine Acyl transferase 1, favouring fatty acid oxidation. 
Therefore it was concluded that FGF 19 might improve dyslipidemia, reduce 
adiposity and body weight and also improve insulin sensitivity78. 
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                 In this study, in patients with Metabolic syndrome, serum levels of FGF 
19 (135.02 ± 20.76 pg/ml) are significantly lower than that of the healthy controls 
(266.34 ± 65.5 pg/ml). 
                 Additionally, Serum TGL and HDL-C also differed significantly 
between cases and controls. Comparison of mean value of AIP of the controls 
(0.36± 0.06) and the cases (0.79± 0.12) showed a significant rise in the cases.  
                  Pearson correlation showed negative correlation between FGF 19 and 
other cardiovascular risk factors like TGL and AIP and a positive correlation with 
cardio protective factors like HDL.                                  
                   In patients with Metabolic syndrome, obesity is a main factor 
contributing to Insulin resistance, which plays a potent role in the pathogenesis of 
Cardiovascular diseases. Obesity also promotes atherogenic dyslipidemia. 
Dyslipidemia favours development of CVD. Hyper triglyceridemia is an 
independent risk factor for CVD. FGF 19 increases fatty acid oxidation, which 
decreases the concentration of triglycerides. Hence, a low FGF 19 level is 
invariably associated with increased atherogenity of plasma, leading on to 
Cardiovascular diseases.  
                  Hence these observations suggest that FGF 19 is a novel marker of 
Metabolic syndrome and is used to assess cardiovascular risk in patients with 
Metabolic syndrome. 
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CONCLUSION 
 
                 This study shows that serum levels of FGF 19 are low in patients with 
Metabolic syndrome. The negative relationship obtained between FGF 19 and 
several other known cardiovascular risk factors like TGL and log (TGL / HDL-C) 
suggests that FGF 19 can be used as a novel marker in assessing cardiovascular 
risk in patients with Metabolic syndrome.  
                Hence, earlier intervention can be taken to reduce the cardiovascular 
complications. 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF 
THE STUDY 
 
 
 
 
 
 
 
 
133 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
                     The study has the following limitations: 
1. This is a pilot study including a small number of patients and controls. 
2. Other valuable relevant markers like fasting Insulin, hsCRP, HbA1C were 
not included in the study. 
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FUTURE SCOPE OF THE STUDY 
 
TREATMENT WITH FGF 19 IN METABOLIC SYNDROME:  
                 In patients with obesity, metabolic syndrome and non alcoholic fatty 
liver, FGF 19 serum levels has been decreased 56,61. And these three diseases 
predisposes to Coronary Artery Disease (CAD). Hence studies concluded that 
FGF 19 has its own contribution to CAD56. 
                  FGF 19 has beneficial effects on metabolism of Carbohydrates and 
Lipid. FGF 19 can be supplemented as a treatment modality in metabolic 
disorders69. FGF 19 can be used as a potential target for treating dyslipidemia3.  
                 Therapies with recombinant FGF 19 is under research to treat diabetes 
and bile acid disorders51. FGF 19 is considered as a new weapon to combat 
increasing incidence of obesity, metabolic syndrome and type 2 Diabetes. It helps 
to explore potential targets for treating the metabolic disorders78. 
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A STUDY OF SERUM LEVEL OF FIBROBLAST GROWTH FACTOR-19 
IN METABOLIC SYNDROME 
PROFORMA 
NAME OF THE PATIENT : 
AGE    : 
OCCUPATION  : 
ADDRESS   : 
COMPLAINTS  : 
PAST HISTORY  : 
PERSONAL HISTORY : 
FAMILY HISTORY  : 
DRUG HISTORY  : 
GENERAL EXAMINATION:          
                HT:                                 WT:                                    BMI:               
                BP:                                 PR:                      WAIST CIRCUMFERENCE: 
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SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                       
                                            ABD:                                                  CNS:                                                                                    
INVESTIGATIONS : 
1.  BLOOD SUGAR:                            FBS   :                    
                                                                          PPBS   : 
2. LIPID PROFILE:    TOTAL CHOLESTEROL: 
                                 
                                TRIGLYCERIDES            : 
                                            HDL-C                              : 
                                            LDL-C                               : 
                                            VLDL                                : 
3. SERUM FGF 19: 
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CONSENT FORM 
 
                     Dr.S.ARUNA, post graduate student in the department of 
Biochemistry, Thanjavur medical college, Thanjavur is doing ‘A study of 
serum level of Fibroblast Growth Factor-19 in Metabolic Syndrome’. 
The procedure has been explained to me clearly. I understand that there are 
no risks involved in the above procedures. I hereby give my consent to 
participate in this study. The data obtained here may be used for research 
and publication. 
 
Signature: 
 
Name: 
 
Place:  
 
 
